JOURNAL INFORMATION

Definition

Thrita is an international, peer-reviewed, open access, quarterly journal funded by Prof. Parvin Pasalar. Thrita is the official journal of Kowsar Corporation in scientific collaboration with Tehran Students’ Research Centers Network (TSRCN). Kowsar Corporation acts as a science, technology and medicine (STM) publisher which publishes more than 45 journals in different fields of sciences. Tehran Students’ Research Centers Network is an academic student organization that includes Students’ Scientific Research Centers of 8 medical universities of Tehran.

Scope

Thrita publishes the latest researches and findings those performed by medical sciences researchers all over the world.

Scientific-Research Approval

We are honored to inform our readers that Thrita has succeeded to receive Scientific-Research Approval of the Commission for Accreditation and Improvement of Iranian Medical Journals.

<table>
<thead>
<tr>
<th>Full Journal Title</th>
<th>Thrita</th>
</tr>
</thead>
<tbody>
<tr>
<td>JCR Abbreviation Title</td>
<td>Thrita</td>
</tr>
<tr>
<td>ISO Abbreviation Title</td>
<td>THRITA</td>
</tr>
<tr>
<td>Category</td>
<td>Medicine</td>
</tr>
<tr>
<td>p-ISSN</td>
<td>2352-0612</td>
</tr>
<tr>
<td>e-ISSN</td>
<td>2352-0620</td>
</tr>
<tr>
<td>Language</td>
<td>English</td>
</tr>
<tr>
<td>Journal Country / Territory</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Frequency</td>
<td>Quarterly</td>
</tr>
<tr>
<td>Indexing Sources</td>
<td>Google Scholar, Index Copernicus, WHO-EMRO Index Medicus, Islamic World Science Citation Center (ISC), Scientific Information Database (SID), Iranmedex, Magiran</td>
</tr>
<tr>
<td>Online Submission</td>
<td><a href="http://www.thritajournal.com">www.thritajournal.com</a></td>
</tr>
<tr>
<td>Distribution</td>
<td>Among all subscribers, 15% of them are in European countries, 10% in USA &amp; Canada, and 70% of them are in the Middle East &amp; Middle Asia. This calculation is not based on online users or consortia customers.</td>
</tr>
<tr>
<td>Price</td>
<td>Online: Open Access; Hard-copy: 30$</td>
</tr>
<tr>
<td>Contact Information</td>
<td>Postal Address: No.56, Vesal Shirazi St, Tehran, IR Iran. Tel/Fax: +98-2188989161</td>
</tr>
<tr>
<td></td>
<td>Electronic Address: Website: <a href="http://www.thritajournal.com">www.thritajournal.com</a> E-mail: <a href="mailto:info@thritajournal.com">info@thritajournal.com</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Kowsar Corp.</td>
</tr>
<tr>
<td></td>
<td>Central Office: Postal Address: Patersweg 22, 6431 GC, Hoensbroek, Limburg, The Netherlands; Tel/Fax: +31-45 52163 99.</td>
</tr>
<tr>
<td></td>
<td>Regional Office: P.O. Box: 14155-3651, Tehran, IR Iran. Tel: +98-2188352501-4 (ext. 106); Fax: +98-2188352501-4.</td>
</tr>
<tr>
<td></td>
<td>Electronic Address: website: <a href="http://www.kowsarpub.com">www.kowsarpub.com</a>, E-mail: <a href="mailto:info@kowsarpub.com">info@kowsarpub.com</a></td>
</tr>
</tbody>
</table>
DEAR COLLEAGUES,

As the director of Iran Hepatitis Network and Global Hepatitis Community, I would like to mention that viral hepatitis is one of our priority in healthcare system now. The burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in the region mandates us to work more in this issue. We made a link between epidemiologists, clinicians, pathologists, virologists, specialists in transfusion medicine as well as research and laboratory centers from Iran and the world. We would like to facilitate scientific communication between researchers who are working in the field of viral hepatitis and other liver diseases. One of our activity is Tehran Hepatitis Conference which has been held for 5 times yet in Tehran, Iran.

I would like to take great pleasure in inviting you to participate in the 6th International Tehran Hepatitis Conference (THC6) hosted by Iran Hepatitis Network which will take place in Iran, May 2015. In THC5, around 1500 scientists participated and we had distinguished speakers from Canada, South Korea, Germany and the region. I invite all universities, research centers and other scientific professions in hepatology and liver diseases to join us.

In a close collaboration between Iran Hepatitis Network (IHN) and European Association for the Study of the Liver (EASL) the first day of the THC6 will be dedicated to the lectures of scientific leaders of hepatology from Europe and Iran. The Best of EASL day at THC6 will take place 27 May, 2015 with an interesting and comprehensive scientific program concentrated on viral hepatitis and other liver diseases. The guests from EASL will present the new findings in hepatology and the Iranian distinguished speakers will present their experience on management of liver diseases in Iran. We take great pleasure to invite you to participate in the Best of EASL day at THC6 which intends to promote the knowledge of hepatology in Iran and the region.

Kind Regards,

Seyed-Moayed Alavian, M.D.
THC6 Chairman
Professor of Gastroenterology and Hepatology

*Director of Iran Hepatitis Network*
Tel/Fax: +98 21 8126 2072
Tehran, I.R. Iran
editor@hepatmon.com / alavian@thc.ir
THC6 Boards and Committees

HELD BY:
Iran Hepatitis Network
Kowsar Corporation
Baqiyatallah Research Center for Gastroenterology and Liver Disease

THC6 GOVERNING BOARD:
Prof. Seyed-Moayed Alavian, MD, Director of Iran Hepatitis Network, Tehran, IR Iran
Prof. Kamran Bagheri-Lankarani, MD, Shiraz University of Medical Sciences, Shiraz, IR Ira
Prof. Frank Tacke, MD, PhD, University Hospital Aachen, Aachen, Germany

EXECUTIVE MANAGER:
Dr. Heidar Sharafi, PhDc, Iran Hepatitis Network, Tehran, IR Iran

SCIENTIFIC COORDINATOR:
Khashayar Hesamizadeh, MSc

BASIC SCIENCE MANAGERS:
Seyed Mohammad Jazayeri, MD, PhD
Seyed Mohammad Miri, MD, PhDc

INTERNATIONAL AFFAIRS & COMMUNICATION MANAGER:
Monir Niazi, Manager of Gastroenterology and Hepatology Center, Tehran, IR Iran
Leila Mehrnoush, MD Hepatology International Affair Manager / Iran - Azerbaijan
Shima Salimi, MD Coordinator for communication with DIC and MMT centers

SCIENTIFIC COMMITTEE:
Adibi P, MD
Alavani SM, MD
Ataei B, MD
Alavi-Moghadam M, MD
Behnava B, MD
Einollahi B, MD
Fattahi MR, MD
HasanjaniRoshan MR, MD
Jazayeri SM, MD
Jarijani A, PhD
Hajariizadeh B, MD, PhD
Keshvari M, MD

Keyvan H, PhD
Lankarani KB, MD
Mahboobi N, DDS
Mansouri S, MD
Mansour-Ghanaei F, MD
Mardani M, MD
Merat S, MD
Mohammad-Nejad M, MD
Miri SM, MD, PhDc
Nabavi M, MD
Naseri Moghadam S, MD
Nikbin M, MD

Pourhoseingholi MA, PhD
Roohvand F, PhD
Saber Firoozi M, MD
Sali S, MD
Sayyad B, MD
Sefi Zareie B, MD
Somi M, MD
Sharafi H, PhDc
Shekarabi M, MD
Yadegari D, MD
Zamani F, MD
THC6 Boards and Committees

IT COMMITTEE:
Meisam Fathi, Head
Javad Karimi
Ali Hedeshi
Shahnaz Yari
Samira Nateghi

EXECUTIVE COMMITTEE:
Mehdi Ashour
Mohammad Ali Sarami
Seyed Abbas Alavian
Seyed Ehsan Alavian
Vahid Haghani
Farshad Abdolrahimi
Shahla Bordbar
Saeedeh Ebadat
Maryam Ahmadi
Samira Ahmadi
Arezoo Mirzaee
Marzieh Taheri
Amir Hesam Nemati
Hosein Noroozian
Majid Asgar
Mohammad Taghi Borjian
Bahman Aghcheli
Saeed Ghorbani

SECRETARIAT COMMITTEE:
Bent-al-Hoda Beyram, Head
Elham Jannati
Maryam Nima
Maryam Padami
Arash Bordbar

STUDENTS’ (YOUNG INVESTIGATOR) SCIENTIFIC COMMITTEE:
Hamidreza Karimi-Sari, Head
Maani Beigy
Reza Ajudani
Elham Maserat
Masoome Rezaee asl
Fardin Dolatimehr
Mohammad Hossein Khosravi
Farbad Pishgar
Mahdi Faridchehr
Sarvenaz Shaaheen
Sarah Ala
Maryam Tajik
Mahdi Safiabadi
Mohammad Saeid Rezaee-Zavareh
Mohammad Ehsan Bayatpoor

EDITORIAL BOARD:
Abtahi H, MD
Akhavan niaki H, MD
Alavi SM, MD
Aflatoonian MR, MD
Agha Sadeghi MR, MD
Aghazadeh R, MD
Ayatollahi J, MD
Davoodian P, MD
Ebrahimi Daryani N, MD
Fattahi Abdizadeh M, PhD Godarzi MT, MD
Golsa R, MD
Hashemi Tabar M, MD
Hoseini A, MD
Joghataee MT, PhD
Kalantari H, MD
Karimzadeh H, PhDc
Khaleghi nia S, MD
Malekzadeh R, MD
Mardani M, MD
Metanat M, MD
Mirmajlesi H, MD
Mohraz M, MD
Mohammadzadeh M, MD
Motezaker M, MD
Naghili B, MD
Naser poor T, MD
Nassiri-Toosi M, MD
Pirouzi A, MD
Rafiee AR, MD
Ranjbar R, PhD
Saneie Moghadam E, DCLS
Semnani S, MD
Shahbazi M, MD
Shahi H, MD
Sheikh Esmaeli F, MD
Soltani Tehrani B, MD
Tavalaei M, MD
Vahdat K, MD
Yadegari nia D, MD
Zali MR, MD
Ziaie M, MD
**O099 EFFECT OF CHLOROQUINE THERAPY ON ANTHROPOMETRIC PARAMETERS, VIT D3, FERRITIN AND BIOCHEMISTRY PARAMETERS AT HCV INFECTION PATIENTS: PILOT TRIAL.**

Payam Peymani1, Behzad Yeganeh2, Saeid Ghavami3, Siamak Sabouri4, Bita Geramizadeh1, Mohammad Reza Fattahi5, Hossein Keyvani2, Negar Azarpira4, Maryam Akbari1, Kevin M Coombs6, Kamran B Lankarani1

1Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 2Hospital for Sick Children Research Institute, Department of Physiology & Experimental Medicine, University of Toronto, Toronto, Canada; 3Department of Human Anatomy and Cell Science, St. Boniface Research Centre, Manitoba Institute of Child Health, Biology of Breathing Theme, University of Manitoba, Winnipeg, Canada; 4Safety Promotion and Injury Prevention Research Center and Department of Clinical Epidemiology, School of Health, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran; 5Department of Pathology and Organ Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 6Department of Internal Medicine and Gastroenterology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran; 7Department of Clinical Virology, Iran University of Medical Sciences, Tehran, Iran; 8Organ Transplant Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Zand Street, Shiraz, Iran; 9Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada

**ABSTRACT**

**Objective:** Hepatitis C virus infection frequently leads to chronic hepatitis C which may progress to cirrhosis and even to hepatocellular carcinoma. This study aimed to investigate the effective parameters in patients chronically infected with HCV with non-response criteria and chloroquine therapy.

**Methods:** This study is the continuation of our previous paper with method Triple-blind, Randomized Controlled Pilot Study. Patients after understood the study procedures and signed informed consent, they randomized into treatment group (Chloroquine 150 mg once daily, for 8 weeks) and control group (placebo once daily, for 8 weeks). The inclusion criteria was including male, between 18 and 60 years of age, confirmed chronic hepatitis C with non-response criteria, Genotype 1. Data were analyzed with an intention to treat perspective of at the end follow up (12 weeks), considering to variables such as anthropometric parameters, Vit D3, Thyroid function, ferritin and biochemistry parameters evaluated. All statistical analyses were performed using SPSS for Windows (Version 10 SPSS Inc, Chicago, IL, USA).

**Results:** Our results showed a decrease in median AST from 48 to 33, ALT from 57 to 42(p=0.03), Cholesterol 144 to 131(p=0.04), TG 86 to 67 and Ferritin levels in plasma samples of chloroquine treated patients at the end of the first follow up (week 4) and second follow up(weeks 8-end of treatment).

**Conclusions:** According to the results suggest that a chloroquine therapy may be very useful for HCV treatment in patients that are non-response and, it help to normalize some biochemical, ferritin and vitamin D status.


**O129 A COST-UTILITY ANALYSIS OF DIFFERENT ORAL ANTIVIRAL MEDICATIONS IN PATIENTS WITH CHRONIC HEPATITIS B IN IRAN: A MICRO-SIMULATION ECONOMIC DECISION MODEL.**

Khosro Keshavarzi1, Abbas Kebriraezaeadeh1, Seyed Moayed Alaviani2, Shokoufeh Nikfar3, Ali Akbari Sari1, Farid Abedin Dorkoosh1, Maryam Keshvari4, Mohsen Rezaei Hemami5

1Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 2Bagyatallah Research Center for Gastroenterology and Liver Diseases, Bagyatallah University of Medical Sciences, Tehran, Iran; 3Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, Iran; 4Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; 5Rasul Akram Hospital, Tehran, Iran

**Presenting Author:** Khosro Keshavarzi, Email: kkheshavarzi2007@gmail.com

**ABSTRACT**

**Introduction:** Although hepatitis B infection is the major cause of chronic liver disease in Iran, no study has been carried out yet in the country to make an economic evaluation of medications in patients with chronic hepatitis B (CHB). Therefore, it is unknown what the cost-effectiveness of different options of medication therapy for this disease is regarding to the local conditions of the country.

**Objective:** The aim of this study is to compare the cost-utility of medication strategies in patients with chronic hepatitis B infection in Iran.

**Methods:** An economic evaluation of cost-utility was conducted to assess five oral medication strategies including: Adefovir, Lamivudine, Adefovir + Lamivudine, Entecavir, and Tenofovir. A Markov micro-simulation model was used to estimate the clinical and economic outcomes in a life time horizon based on societal perspective. Medical and non-medical direct costs and indirect costs were included in the study and Life-Years Gained (LYG) and Quality-Adjusted Life-Years (QALY) were used as outcome measure. The decision model was a Markov Micro-simulation model and continued to run for 10 years with a time horizon of 10 years. The expected outcome of this model was determined through the discount rate of 3%. For the cost of medication, it was considered as a fixed cost and based on the current price of medications in the Iranian market. The cost of medical consumption was determined based on the latest episode of drug consumption in Iran. In the current study, the lifetime horizon was considered for all strategies. The results were compared using Markov Micro-simulation model and compared with each other using a Markov Markov Micro-simulation model and compared with each other using a Markov Micro-simulation model.
Life-Years (QALY) were determined as the measure of effectiveness. The results were presented in terms of Incremental Cost Effectiveness Ratio (ICER) per QALY or LYG. The model was consisted of nine states of the disease; the transition probabilities for the movement between the states were obtained using expert opinions and clinical evidences collected from all over the world. Probabilistic sensitivity analyses (PSA) was used to measure the effects of uncertainty in model parameters.

**Results:** Finding showed the Tenofovir treatment strategy was more effective and less costly than other oral medication strategies. In addition, Tenofovir had the highest QALY and LYG for the HBeAg -ve and HBeAg +ve with 13.52 and 21.53 (discounted) in all comparisons, respectively. Also, PSA proved the robustness of the model results. So that, the cost-effectiveness acceptability curves showed that Tenofovir was the most cost-effective treatment in 86.1% and 87.7% of the simulations for the HBeAg -ve and HBeAg +ve with willingness to pay (WTP) thresholds less than purchasing power parity (PPP) $ 45270 (maximum WTP per QALY), respectively.

**Discussion and Conclusion:** Regarding to The results, using Tenofovir in patients with CHB was a highly cost-effective strategy; in addition, compared with other available medication options, Tenofovir was the most cost-saving strategy which could be the best option utilized as a first-line medication and also be used as a switch for other medications.

**O149 HEPATITIS D VIRUS PROMOTES INHIBITORY EFFECTS ON REPLICATION OF HEPATITIS B VIRUS ISOLATES CONTAINING PRECORE AND BASAL CORE PROMOTER MUTATIONS**

Elham Shirvani-Dastgerdi1, Samad Amini-Bavil-Olyae2, Ulf Herbers1, Eray Yagmur1, Seyed Moayed Alavian3, Christian Trautwein1, Frank Tacke1

1Department of Medicine III, RWTH-University Hospital Aachen, Aachen, Germany;
2Molecular Microbiology and Immunology Department, Keck School of Medicine, University of Southern California, Los Angeles, USA;
3Dr. Stein and Colleagues Medical Care Center, Mönchengladbach, Germany;
4Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran

**Abstract**

**Background:** The two commonly seen hepatitis B virus (HBV) genome alterations related to HBeAg negativity, basal core promoter and precore mutations (BCP: A1762T/G1764A, and PC: G1896A/C1858T, respectively), are associated with a significant increase in HBV viremia in HBV mono-infected patients. However, presence of these mutations in the HBV genome of patients coinfected with hepatitis D virus (HDV) is accompanied with lower levels of HBV DNA in both serum and liver. The aim of this study was to investigate the frequency of PC and BCP mutations in HBV genome of HBV-HDV infected patients with active HBV replication and to assess the functional impact of HDV on mutant HBV replication in vitro.

**Methods:** Serum samples from 71 consecutive HBV-HDV infected patients were collected, PCR amplified, sequenced and analyzed to compare HBV genome alterations between replicative isolates of HBV in HBV mono- and HBV-HDV double-infected individuals, in a case-control study. Replication competent HBV L.28 plasmid vectors (genotype A, subtype adw2) containing wild-type sequence or PC (G1896A/C1858T) and BCP (A1762T/G1764A) mutations, were applied for transient transfection of Huh7 human hepatoma cells, alone (HBV-mono transfection) or along with HDV pcDNA3.1-D2 vector (HBV-HDV double transfection). HBV progeny DNA and HBV-DNA from released virions were detected and quantified to evaluate intra- and extra-cellular HBV replication.

**Results:** Among 71 HBV-HDV infected patients, 24 had detectable HBV replication, allowing successful HBV sequencing in 19 cases which were matched with 38 sequences from HBV infected patients (control). PC and BCP mutations were frequent in mono-, but scarcely found in HBV-HDV infected patients with active HBV replication. Functionally, co-transfection of HBV mutants with HDV strongly reduced the replication of PC- or BCP-carrying HBV constructs.

**Conclusion:** In conclusion, our study confirmed the prior investigations reporting a predominance of wild type precore HBV and lower frequency of BCP mutations in HBeAg negative patients in HBV-HDV co-infections. Moreover, our observations suggest that delta hepatitis can endorse selective adaptations in HBV through assortment of isolates with preferentially wild type PC/BCP domains more likely to escape inhibitory effects of HDV.

**O228 NON-INVASIVE SERUM FIBROSIS MARKERS: A STUDY IN CHRONIC HEPATITIS**

Mohammadreza Abdollahi1, Neda Khalilian2, Aliasghar Pouri1, Mohammadhossein Somi1

1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
ABSTRACT
Introduction: Chronic hepatitis is specified as inflammatory disease of the liver lasting for more than six months. Role of noninvasive fibrosis markers as prognostication factors of the presence or absence of significant fibrosis on liver biopsy of patients with chronic hepatitis is the aim of this study.
Methods: Two hundred twenty-one patients with chronic hepatitis involved in the study between 2011 and 2013. Routine biochemical indices and serum fibrosis markers such as aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), AST to platelet ratio index (APRI) and Fibrosis 4 score (FIB-4) were evaluated, and the histological grade and stage of the liver biopsy specimens were scored according to the Ishak scoring system. Diagnostic accuracies of these markers for prediction of significant fibrosis were assessed by Receiver Operating Characteristic (ROC) curve analysis.
Results: Contemporaneous laboratory indices for imputing AAR, APRI, and FIB-4 were identified with liver biopsies. From all, 135 males (61.1%) and 86 females (38.9%), with mean age of 39.6±14.4 were studied. Significant correlation between stages of fibrosis and FIB-4, APRI and AAR were detected, with a correlation coefficient higher than that of other markers in the patients with Hepatitis B (r = 0.46), C (r = 0.58) and autoimmune hepatitis (r = 0.28). FIB-4 (AUROC = 0.84) and APRI (AUROC = 0.78) were superior to AAR at distinguishing severe fibrosis from mild-to-moderate fibrosis and gave the highest diagnostic accuracy.
Conclusions: Application of these markers was good at distinguishing significant fibrosis and decreased the need for staging liver biopsy specimens among patients with chronic hepatitis.

O232 CANOLA (Brassica napus) OILSEEDS AND EXTRACTS AS NOVEL AND SUPERIOR TOOLS IN FORMULATION OF A PLANT-BASED HCV VACCINE CANDIDATE

Sara Mohammadzadeh, Soheilla Ajdary, Ali Hatif Salmanian, Parastoo Ehsani, Farzin Roohvand

ABSTRACT
Hepatitis C virus (HCV) with 3% prevalence, is the leading cause of chronic liver diseases and cirrhosis worldwide. Despite introduction of recent antiviral treatments, development of a vaccine remains the most cost-effective means for global eradication of HCV, while none is available to date. The oilseeds of “canola (Brassica napus)” are relatively new plant-based platform for expression and formulation of recombinant immunogens via utilization of their oil-bodies as adjuvant. Herein, N-terminal hydrophilic region (413 bp) of HCV capsid (core) protein (HCVcp; synthetic codon-optimized gene) was inserted into the pBII400 binary vector and transformed into canola via Agrobacterium tumefaciens mediated transformation. Transgenic plants confirmed by PCR at DNA level (via specific primers) and by western blotting at protein level (via specific antibodies). Quantification analyses by ELISA indicated expression yields around 10μg of HCVcp/gram of seed. Immunization studies in BALB/c mice for canola-derived HCVcp (cHCVcp) compared to NI-NTA purified E.coli-derived HCVcp (eHCVcp) indicated that cHCVcp could elicit almost similar immune responses in 10x lower concentrations than eHCVcp (0.35 vs 3.0 μg/injection/animal). Besides, immunization by cHCVcp elicited higher IFN-α & IL-4 cytokines (Th1/Th2 responses) at both protein and mRNA levels compared to that of eHCVcp (assessed by ELISA & RT-PCR respectively) while generally oil extracts of canola as an adjuvant demonstrated a better eliciting profile of IFN-α For both cHCVcp and eHCVcp compared to that of Freund. Results of this study indicated that canola (as a plant-based expression platform) and its oil extracts might be superior for formulation of HCV vaccine candidates.

O253 IMMUNE RESPONSES TO A CD8-CTL EPITOPE OF N HCV CORE PROTEIN (AA: 39-48) IN THE CONTEXT OF A SYNTHETIC POLYTOPE AND NATIVE PROTEIN-A COMPARATIVE STUDY

Maryam Yazdanian, Arash Memarnejadian, Mehdi Mahdavi, Hossein Khanahmad, Hoorieh Soleimanjahi, Farzin Roohvand

1Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran;
2Virology Department, Pasteur Institute of Iran, Tehran, Iran;
3BCC Department, Pasteur Institute of Iran, Karaj, Iran;
4Virology Department, Tarbiyat Modares University, Tehran, Iran

Presenting Author: Maryam Yazdanian, Email: myazdanian2000@gmail.com
ABSTRACT

Hepatitis C virus (HCV), a positive strand RNA virus encoding for three structural (Core, Envelope 1 and 2) and seven nonstructural (NS) proteins, is the main cause of chronic liver inflammation and cirrhosis globally while no vaccine for this viral infection is available to date. Although introduction of Direct Antiviral Agents (DAAs) against HCV in recent years provided revolutionized treatment approaches, but due to the high cost and number of therapeutic limitations, availability of a vaccine is the only possible way for global eradication of HCV. Enhancement of cellular responses, CD8+ CTLs and Th1 cytokines by T-cell based vaccines is a recognized approach in HCV vaccine design and accordingly more recently, for the first time a clinical trial (NCT01436357) by a T-cell viral vector-based prophylactic HCV vaccine was started. In this context, HCV polytopic peptides (HCVpp) based on isolated-T cell epitopes arranged in tandem has also gained importance but the immune potency of a single epitope in the context of polytope compared to the natural protein is not known. To this end, an HCVpp containing dominant H-2d and HLA-A2-restricted CD8+ CTL epitopes of HCV proteins including: C (Core; aa 132-142), E2 (Envelope2; aa 614-622), N (NS3; aa 1405-1414), Ei (Envelopei; aa 405-414) and Ci(core; aa 39-48) in tandem of CE2NiC1 was synthesized. In design of the HCVpp, different algorithms were employed to optimize the proteasome mediated epitope processing and minimize the creation of junctional epitopes. To obtain HCV core protein containing C1 epitope, N-terminal hydrophilic region (413 bp) of HCV core protein (HCVcp) in backbone of pIVEX2.4a vector was expressed in E.coli BL21-A1 and purified by Ni-NTA agarose beads as previously described (roohvand et al, JBC, 2009). Pluronic acid F127 as a human compatible adjuvant was used in formulation of the immunogens (HCVcp & HCVpp) and groups of BALB/c mice were immunized by the immunogens and controls (antigen free adjuvant and PBS). Evaluation of immune responses by proliferation assay (the non-radioactive colorimetric method of Cell Proliferation ELISA BrdU), Interferon gamma-Elispot and in vivo CTL assay (Carboxy Fluorescein diacetate, succinimidyl Ester (CFSE) dye method) for the H-2d-C1 epitope indicated that percentage of specific lysis (CTLs) and IL-4 values for both immunogen (HCVcp and HCVpp) were statistically identical while proliferation rate and IFN-γ Levels were slightly in favor of HCVcp. Results of this study indicated the proper induction of cellular responses towards isolated CD8-CTL epitopes in context of a polytope compared to that of the native protein.

O257 TRANSFECTION OF INSECT CELLS (SF9) BY RECOMBINANT BACULOVIRUS CONTAINING HCV CORE+1 OF GENOTYPE JFH1

Farideh Sadat Sajadian Fard1, Pooneh Rahimi2, Fatemeh Fotouhi Chahouki1, RoohAllah Vahabpour4

1Islamic Azad University, Pharmaceutical Science Branch, Tehran, Iran;
2Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran;
3Influenza Research Laboratory, Pasteur Institute of Iran, Tehran, Iran;
4Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

Presenting Author: Farideh Sadat Sajadian Fard, Email: faridesajadianfard@gmail.com

ABSTRACT

Background: Recently, a new protein, named Core+1, has been described to be produced through a +1 ribosomal frame shift in the Core protein coding region in Hepatitis C virus. The purpose of this study was to design and build a recombinant baculovirus vector containing HCV (JFH1) Core+1 sequence and confirm the expression of recombinant protein Core+1 in insect cells.

Material and Methods: Core+1 gene of HCV (JFH1) was synthesized commercially into pUC57 plasmid. Then the synthesized target gene was subcloned into the plasmid pFastBac-HTA. The recombinant vector was used to transform the competent E.coli DH10Bac containing the donor clone. The recombinant baculovirus bacmid was produced following transposition. Recombinant bacmid was verified by PCR and then transfected into SF9 insect cells to package a new recombinant baculovirus.

Results: Sequence analysis and white-blue colony selection confirmed that the Core+1 sequence from HCV (JFH1) was successfully cloned into the pFastBac-HTA vector which was used to transform the E.coli DH10Bac. SF9 cells were transfected using the recombinant bacmid.

Conclusions: Design and construct the recombinant baculovirus vector containing the HCV (JFH1) Core+1 sequence was performed for the first time. Baculovirus expression system provides a high yield post-translational modification tool for HCV Core+1 protein expression which is similar to Core+1 protein that produced during natural infection with HCV.

O274 MOLECULAR CHARACTERIZATION AND FUNCTIONAL ANALYSIS OF HEPATITIS B SURFACE GENE IN HIV POSITIVE PATIENTS WITH OCCULT HEPATITIS B INFECTION
Ahmadreza Sadeghi, Frank Tacke1, Seyed Mohammad Jazayeri1
1Medical virology (Hepatitis B molecular Lab), School of Public Health / Tehran University of Medical Sciences, Tehran, Iran; 2Mediklinik III, Aachen University Hospital, Aachen, Germany

Presenting Author: Ahmadreza Sadeghi, Email: sadeghi@tums.ac.ir

ABSTRACT

Background: Occult hepatitis B virus infection (OBI) is described by the presence of HBV DNA with negative HBV surface protein (HBsAg) in the serum outside the seroconversion window period of HBV infection. Occult HBV infection in HIV co-infected patients has been well recognized as a clinical entity.

Objectives: The aim of this study was to determine the hepatitis B virus small surface gene mutations in OBI positive, HIV co-infected patients which might be related to the emergence of occult HBV infection and evaluation of the impact of those mutations on the expression of small surface gene and its excretion in HUH7 cells using commercial diagnostics.

Materials and Methods: Viral DNA was extracted from the serum of 166 Iranian HIV infected patients with negative HBsAg status whom referred to Iranian research center for HIV/AIDS who had previously tested for HBV DNA by real time PCR. 25 of sera from OBI cases were selected for nested PCR. Nested PCR was performed to amplify small surface gene. Following direct sequencing and mutational analysis, we observed a high frequency of P127T, P127L and S136Y mutations in our study population. We further constructed the expression vectors encoding wild type as well as mutants genotype D HBsAg to analyze the effects of these mutations through transient transfection of HUH7 cells. For extra and intracellular expression assay, the supernatant and cell lysate were harvested and subsequently tested quantitatively for HBsAg in the third day post-experiment.

Results: Quantification of expressed HBsAg in supernatants and cell lysates revealed that there was a significant reduction in mutants compared to wild type. This expression reduction in cell lysates were consistent with corresponding supernatants.

Conclusions: Among the plenty etiologic factors supposed for occult Hepatitis B virus infection, we found HBsAg mutations which are associated with reduced HBsAg detection. Further analyses of these mutations may lead us to understand the mechanisms related to occult HBV and to design strategies for a better control of the infection.

O281 INTRODUCING A MATHEMATICAL ALGORITHM FOR PREDICTING VIRAL LOAD IN HBV INFECTED SUBJECTS USING SURROGATE MARKERS

Hiva Sharebiani1, Sepideh Saleh Abadi2, Sanaz Ahmadi Ghezeldashti3, S.A.Rahim Rezaee1
1Student Research Committee, Faculty of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran; 2Inflammation and Infectious Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; 3Research Centre for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Centre for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, Iran.

Presenting Author: Hiva Sharebiani, Email: hivasharebiani@yahoo.com

ABSTRACT

Background: Suitable methods for personalized clinical monitoring of HBV-infected patients are very crucial in resource-poor setting areas. Therefore, finding surrogate markers as predictive indicators for monitoring of these patients is an important need.

Materials and Methods: Demographic data and laboratory findings including age, gender and SGOT, SGPT and viral load (Arthus, Qigen, Germany) for 100 HBV infected subjects were collected at the first admission from 2011 to 2013. Data mining (Rapid Miner, V5.3 and mathematical tools were carried out for investigation. Decision tree was developed to forecast viral loads according to age, gender, SGOT and SGPT and the pathways for these levels. Naive bayes algorithms then were used to calculate probability of these pathways.

Results: In this study probability of having viral load more than 106 copies/ml was 0.59 and for less than 105 is 0.41. It could be possible to predict the viral load for every patient. The sensitivity and specificity of this algorithm for prediction of viral load were 100% and 71% respectively. However, the method needs a comprehensive cohort study for a reliable mathematical algorithm. Decision tree was presented in a separated file.

Conclusions: Mathematical analysis and data mining findings according to these algorithms could be considered as valuable markers for introducing a surrogate algorithm for personalized monitoring of HBV-infected subjects and starting anti-viral therapy in the absence of sophisticated detection assays.
O282 DIAGNOSIS OF HEPATITIS DISEASE USING FUZZY K NEAREST NEIGHBOR APPROACH

Bita Baran¹

¹Faculty of Computer, Mashhad, Mashhad, Iran

Presenting Author: Bita Baran, Email: bitabebaran@chmail.ir

ABSTRACT

In this paper, we present an effective and efficient diagnosis system using fuzzy k-nearest neighbor (FKNN) for Hepatitis diagnosis. The proposed FKNN-based system is compared with the support vector machines (SVM) based approaches. In order to further improve the diagnosis accuracy for detection of Hepatitis, the principle component analysis was employed to construct the most discriminative new feature sets on which the optimal FKNN model was constructed. The effectiveness of the proposed system has been rigorously estimated on a Hepatitis data set in terms of classification accuracy, sensitivity, specificity and the area under the receiver operating characteristic (ROC) curve (AUC). Experimental results have demonstrated that the FKNN-based system greatly outperforms SVM-based approaches and other methods in the literature. The best classification accuracy obtained by the FKNN based system using a 10-fold cross validation method can ensure a reliable diagnostic model for detection of Hepatitis. Promisingly, the proposed system might serve as a new candidate of powerful tools for diagnosing Hepatitis with excellent performance.

Poster Presentations
Poster Presentations

P067 NATURAL HISTORY OF CHRONIC HBV INFECTION: A COHORT STUDY WITH UP TO 11 YEARS FOLLOW-UP IN BIRJAND HEPATITIS CLINIC, IN EAST OF IRAN

Masoud Ziaee, Tahereh Darvishpour kakhki, Bita Bijari, Ghodsieh Azarkar

1Internal Medicine, Hepatitis Research Center, Birjand, Iran; 2Ophthalmology, Hepatitis Research Center, Tehran, Iran; 3Community Medicine, Hepatitis Research Center, Birjand, Iran; 4Radiology, Hepatitis Research Center, Birjand, Iran

Presenting Author: Tahereh Darvishpour kakhki, Email: taherehdarvishpour@gmail.com

ABSTRACT
Background: Infection with hepatitis B virus (HBV) is a major medical problem in the world. Hepatitis B Virus (HBV) has infected approximately 2 billion people worldwide, of whom more than 350 Million are chronically infected. Considering that every year millions of hepatocellular carcinoma and cirrhosis following viral infection of the liver, lose their lives, follow up course of the disease and to determine prognosis and influence of treatment on progression disease is very important.

Objective: The present study aims to Follow up of patients with chronic hepatitis B(CHB) infection in Birjand Hepatitis Clinic, in east of Iran.

Materials and Methods: A cohort study was conducted on 235 chronic hepatitis B patients which followed at least three years in the years 2002-2013. All patients that the conditions in the study were retrospectively retrieved from the archive clinics were prepared and the checklist. Data analysis and descriptive analysis using SPSS 20 software using mean and standard deviation of proportions and the t-test and chi-square analysis was performed.

Results: The study was conducted on 235 patients. The mean age of the subjects were 33.36±11.132 (56.2%) were male and 103(43.8) were females and 193(82.1%) of patients were married. The average of follow-up period was 5.26 ± 1.9 years (3-11). 10 patients (4.3 %) HBsAg-negative patients during the study. Based on the this study results 45 patients (19.1%) HBeAg were positive that, 17 patients (38%) of them were HBeAg negative. relationship between HBeAg and outcome was statistically significant. (p=0.026) There were 3 patients (1.6%), with Anti HDV positive. In this study of 235 patients who were followed up, 35 (14.9%) in the active stage of the disease were of these 9 patients (3.8%) progress to cirrhosis and in 2 patients (0.3%) of those who had cirrhosis and carcinoma was reported.

Conclusions: The result this study showed that 14.9% of carriers to chronic active hepatitis and finally 4.7% of carriers Progress to complications associated with the disease and only 4.3% are HBsAg-negative patients. Thus, this study showed that the follow-up of these patients to determine their disease status change and the decision to begin necessary treatment and prevention of the importance extension.

P085 HEALTH LITERACY DISPARITIES ABOUT HEPATITIS B: A NATIONAL ASSESSMENT IN IRAN

Kiandokht Bashiri, Nader Roushan

1Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 2Gastroenterology Department, Imam Khomeini Hospital Complex, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Presenting Author: Kiandokht Bashiri, Email: bashiri_kian@yahoo.com

ABSTRACT
Background: Worldwide, about 350 million people are infected with Hepatitis B virus (HBV), most of them in Asia. Up to 1 million of them die due to these sequelues annually. Few studies concerned about the HBV awareness of Iranian young people. As health education programs should be based on the awareness of target group about the disease, we conducted a national survey to evaluate the health literacy and the vaccination status of Iranian young people regarding HBV.

Objectives: The purpose of our study was to find Iranian adolescents’ health literacy deficit about hepatitis B (HBV) and associated factors.

Patients and Methods: We conducted a questionnaire-based national survey of 18-year-old adolescents according to stratified cluster random sampling in Iran during 2007.

Results: Assuming 75% as the appropriate awareness, only 21.3% of adolescents had good literacy about hepatitis B. Lower levels of education, living in urban areas, celibacy and male gender were associated with lower health literacy. The health literacy of HBV infected people about major routes of HBV transmission was low (P < 0.001). According to the participant’s answers, radio and TV as the most important tools for their awareness about HBV; there-
fore, implementing educational campaigns through these media is necessary for Iranian community.

Conclusions: There are important deficits in adolescents’ health literacy about HBV. We should focus on implementing educational campaigns about HBV through media tools for Iranian community.

P093 DETECTION RESIDUAL HOST CELL DNA BY POLYMERASE CHAIN REACTION TECHNIQUE IN RECOMBINANT HEPATITIS B VACCINE

Mana Khodayar1, Mahdi Paryani, Samira Mohammadi-Yeganeh2

1Cellular and Molecular Biology, Tehran East Branch, Islamic Azad University, Tehran, Iran; 2Department of Research and Development, Pasteur Institute of Iran, Tehran, Iran; 3Production and Research Complex, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Presenting Author: Mahdi Paryan, Email: mparyan@gmail.com

ABSTRACT

Background: Biopharmaceutical products such as recombinant HBV vaccines are produced by fermentation using either microbial or eukaryotic cells grown in complex media. Crude preparations of vaccine substances from fermentation contain a number of DNA contaminations from host cells, which are present as impurities. Therefore, removal of the host cell materials is desirable to prevent potential adverse effects. The aim of this study was to develop a sensitive polymerase chain reaction (PCR) method for quantification the level of host-cell DNA (HCD) in recombinant HBV vaccines.

Materials and Methods: we designed specific primers for all strains of Pichia pastoris as a host cell. To determine the specificity of primers, 20 samples from human genome and 10 samples from diverse genomes (Bacteria and viruses) were analyzed. Furthermore, pair-wise alignment using NCBI BLAST program was also performed. To determine the sensitivity of assay, a serial dilution of each standard plasmid from 106 to 101 copies/μl was prepared.

Results: Only Pichia pastoris and no other irrelevant genomes were detected in PCR reaction for determination of specificity of primers. In addition, NCBI BLAST approved that the primers do not attach to any other sequences except all strains of Pichia pastoris. The sensitivity or limit of detection of the assay was determined 6 copies/μl.

Conclusions: WHO reported that the acceptable level of HCDs in biopharmaceutical products is 10 picogram. Therefore this fact confirmed the sensitivity of the assay. The assay introduced here is demonstrated to be suitable for detection the residual DNA from Pichia pastoris in recombinant HBV vaccines.

P094 HEPATITIS A SEROPOSITIVITY AMONG NEWLY ADMITTED MEDICAL STUDENTS OF ISFAHAN, KERMANSHAH, AND HAMEDAN: A SEROPREVALENCE STUDY

Farzin Khorvashi1, Parisa Shoaei2, Bahareh Vakili3, Mohsen Janghorbani1, Behrooz Ataei2, Hamid Rahimi2, Majid Yaran4

1Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; 2Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; 3Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Presenting Author: Parisa Shoaei, Email: shoaei@idrc.mui.ac.ir

ABSTRACT

Background: Health science students are at an increased risk of hepatitis A virus (HAV) infection even under accidental infection. The aims of this study were to assess the seroprevalence of HAV in 1st year medical students and to determine the risk factors of HAV vaccination program among this population.

Materials and Methods: A cross-sectional study was conducted in autumn 2010. A total of 1028 newly admitted medical students in Isfahan, Kermanshah and Hamedan were included in the study. Participant data were obtained through predesigned data collection sheets. A serum sample was obtained for serologic testing for the presence of IgG anti-HAV using a commercially available enzyme-linked immunosorbent assay kit. Descriptive statistics, Chi-square and logistic regression tests were performed for statistical analysis and P < 0.05 was considered as significant.

Results: The prevalence of HAV was detected in Isfahan, Hamedan, and Kermanshah newly admitted students 67.5%, 79.2%, and 50.6% respectively. There were significant relations between anti-HAV (IgG) positivity in drinking water and medical students provinces (P < 0.001, RR = 0.58 and 0.65 respectively). The household size did not significantly influence the anti-HAV (IgG) positivity in studied subjects (P = 0.09, RR = 1.26).

Conclusions: Our results indicate that more than
one-third of the medical students in all three faculties were seronegative for IgG anti-HAV and hence at an increased risk of developing HAV infection as a result of occupational exposure. Therefore, we suggest students in a healthcare set up should undergo vaccination against HAV after prevaccination immunity screening.

**P101 CURCUMIN: A PROMISING NATURAL CHEMOTHERAPEUTIC AGENT IN TREATING HEPATOCELLULAR CARCINOMA**

Majid Sadeghizadeh, Seyed Moayed Alavian, Mahsa Motavaf

*Department of Genetics, Tarbiat Modares University, Tehran, Iran;*  
*Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran*  
**Presenting Author:** Mahsa Motavaf, Email: motavaf.m@gmail.com

**ABSTRACT**

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer worldwide. Unfortunately, it is a relatively chemotherapy-resistant cancer and the outcome of liver resection as well as liver transplantation is unsatisfactory. Thus, there is a critical medical need to investigate and evaluate possible alternative approaches. Curcumin, a naturally occurring yellow pigment isolated from turmeric (Curcuma longa), exhibits chemopreventive and chemotherapeutic properties against tumors in animal models and clinical trials. Experimental evidences suggest that the anti-cancer effect of curcumin is via induction of apoptosis through stimulating pro-apoptotic enzymes such as caspases or via inhibiting cell survival pathways including TGF-beta, Akt, NF-kappaB, AP-1 and JNK. In addition, curcumin has been shown to inhibit vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF)-1alpha, the key factors relevant to development of new blood vessels that feed the tumor and cause it to grow. Curcumin’s therapeutic potential against HCC has been investigated in several recent studies. Curcumin has shown a unique chemotherapeutic effect in reversing diethylnitrosamine (DENA)-induced HCC in rat models, possibly mediated through its pro-apoptotic, anti-oxidant, anti-angiogenic, as well as antiproliferative effects. Furthermore, curcumin was shown to induce mitotic arrest and apoptosis in various hepatoma cell lines. Interestingly curcumin was indicated to prevent metastasis and progression of HCC via inhibiting a member of matrix metalloproteinases, MMP-9. Thus, available findings show promising therapeutic properties of curcumin as a natural chemotherapeutic agent in treating HCC.

**P112 BIOINFORMATICS ANALYSIS IN POLYMERASE GENE OF HEPATITIS B VIRUS ISOLATED FROM IRANIAN PATIENTS**

Ali Namvar, Alireza Azizi Saraji, Niloofar Dokhtkhairkhah, Ali Anvar, Paniz Shirmast

*Department of Genetics, Islamic Azad University, Science and Research Branch, Tehran, Iran;*  
*Department of Medical Virology, Tarbiat Modares University, Tehran, Iran;*  
*Department of Life Science Engineering, faculty of New Sciences and Technology, University of Tehran, Tehran, Iran;*  
*Department of Microbiology and Virology, Zanjan University of Medical Sciences, Zanjan, Iran*  
**Presenting Author:** Ali Namvar, Email: alinamvar@outlook.com

**ABSTRACT**

**Background and Aims:** The HBV genome consist of a partially double-stranded circular DNA molecule whose length corresponds to approximately 3,200 nucleotides. The genome is a compact gene layout composed of 4 overlapping ORFs (polymerase, envelope, core and X) so that in comparison with the length of the genome, the total coding capacity is approximately 1.5 times greater. High rate of mutations in HBV genomes comes from the lack of proof-reading mechanisms due to the virus replication via reverse transcription of an RNA intermediate. The open reading frame (ORF), which codes for the hepatitis B surface protein (HBsAg), is overlapped by the polymerase (P) gene. Therefore, drug-resistance associated mutations in polymerase gene can result in changes in the HBV surface protein which can influence virion secretion as much as mutation introduced in the S ORF by other mechanisms. It is also probable to reduce binding of HBsAg to anti-HBs antibodies. The aim of this study is to assess the frequency of mutations in polymerase gene associated with chronic type B hepatitis.

**Methods:** The overlapping surface and polymerase reading frames of chronic type B hepatitis patients were analyzed using the internet tools such as HBVRegDB, HepSEQ, HBVseq and Geno2pheno. Then, data from different databases were compared.

**Results:** The results showed that some mutations in polymerase gene of HBV isolated from Iranian patients strongly associated with chronic type B hepatitis.

**Conclusion:** According to previous studies, due to the overlapping nature of the open reading frames coding for the polymerase and the surface protein, drug-resistance associated mutations in polymerase gene usually reduces binding of HBsAg to anti-HBs antibodies. So, better understanding of functional
consequences of distinct mutational patterns may help us to guide antiviral strategies and management of chronic HBV infection.

**P122 EVALUATION OF ADDING VITAMIN D TO STANDARD HCV REGIMEN (PEG-INTERFERON PLUS RIBAVIRIN) ON EARLY VIROLOGIC RESPONSE (EVR)**

Hasan Vosooghinia, Abbas Esmaielzadeh, Ladan Goshayeshi, Azita Ganji, Musal Reza Hoseini, Omid Ghanale, Ali Bahari

*Gastroenterology and Hepatology, Mashhad University of Medical Science, Mashhad, Iran*

Presenting Author: Ladan Goshayeshi, Email: ladangosh@yahoo.com

**ABSTRACT**

**Introduction:** Chronic HCV-infected patients tend to have vitamin D deficiency, recent studies found that vitamin D has immunomodulator effect. We therefore assessed the effects of vitamin D supplementation on viral response to PEG-INF/RBV.

**Methods:** In a randomized control trail 60 patients with HCV (30 with genotype 1 and 30 with genotype 2, 3) were randomly divided into two groups, 30 to oral vitamin D supplementation (1600 IU/day maintain serum level > 32 ng/mL) together with 180 μg PEG INF-2a plus oral ribavirin during the treatment and 30 to nonsupplementation (control). The primary end point was undetectable HCVRNA at week 12 of treatment as complete EVR. Vitamin D serum level was measured during treatment at base line, week 4, 12 of treatment.

**Results:** Demographic characteristics were similar in both groups. Vitamin D deficiency (<30 ng/dl) was seen in 58% of patients. Complete RVR rate at week 12 was significantly higher in the vitamin D group with genotype 1 than in the control group with same genotype (93% vs 66% \( P = 0.02 \)). But complete RVR rate in vitamin D group with genotype 2,3 was not more than the control group same genotype (100% vs 86% \( P = 0.63 \)). Baseline serum vitamin D levels were lower at baseline (22 ± 15 ng/mL) and increased after 12 wk vitamin D treatment, to a mean level of (52 ± 38 ng/mL \( P \text{ value}=0.02 \)). Complete EVR was more common in intervention group in patients with genotype 1 (\(P=0.002\)).

**Conclusion:** Vitamin D deficiency was common in HCV patients so adding vitamin D to conventional Peg/RBV therapy for patients with HCV genotype 1 significantly improves viral response.

**P135 SNAPSHOT ON DRUG-RESISTANCE RATE IN NUCLEOS (T)IDE ANALOGUE-NAIVE AND–TREATED PATIENTS WITH CHRONIC HEPATITIS B IN CLINICAL PRACTICE**

Fatemeh Bakhshizadeh, Soheila Hekmat, Maryam Keshwari, Seyed Moayed Alavian, Seyed Mehdi Sadat, Amin Doosti, Fatemeh Moteyalli

*Hepatitis &AIDS Department, Pasteur Institute of Iran, Tehran, Iran; Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran; Epidemiology Department, Pasteur Institute of Iran, Tehran, Iran*

Presenting Author: Fatemeh Bakhshizadeh, Email: fatimabakhshy67@yahoo.com

**ABSTRACT**

**Background & Aims:** Drug resistance resulting from reverse transcriptase (RT) mutations is a major concern with nucleos(t)ide analogues (NAS) treatment in chronic hepatitis B (CHB). The aim of the present study was to determine the prevalence of drug-resistance mutation in NAS-naïve and treated patients with CHB in clinical practice.

**Methods:** The full-length of HBV RT region from 62 NAS-naïve and 125 NAS-treated patients were amplified and directly sequenced. Among the 125 NAS-treated patients, 60 were in the group of receiving a mono-therapy with tenofovir, 17 with lamivudine and 7 with adefovir. The remaining 41 patients were in the group of receiving lamivudine-adefovir combination therapy.

**Results:** The mutational analysis on RT region revealed that 3.2% (2/62) of NAS-naïve and 36% (45/125) of NAS-treated patients carried a virus with at least one drug-resistance mutation. The highest rate of patients with at least one drug resistance mutation was observed in the group of patients receiving lamivudine (94.1% [16/17]) and lamivudine-adefovir (53.6% [22/41]), followed by adefovir (42.8% [3/7]), and tenofovir (6.7% [4/60]).

**Conclusion:** This study showed that more than one-third of NAS-treated Iranian patients carried NAS-resistant HBV strains, and that the HBV mutants associated with resistance to NAS might also present in untreated patients. This suggests the use of anti-HBV drugs with higher genetic barrier and potency in first line therapy.

**P138 FATTY ACIDS IN CEREBROSPINAL FLUID IS CORRELATED WITH LIVER ENZYMES TESTS**
ABSTRACT

Background: Alterations in fatty acid homeostasis have been associated with nonalcoholic fatty liver disease by inducing fat storage. Yet, fatty acids may also indirectly affect hepatic function by acting on the central nervous system. The aim of the present study was to determine whether fatty acids in cerebrospinal fluid (CSF) are independently associated with liver enzymes tests.

Methods: CSF and serum samples were collected from 49 patients (age 18-65) at the university hospitals as part of routine diagnostic testing. Along with serum liver enzymes aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase, the fatty acid composition of CSF was measured by gas-liquid chromatography.

Results: The saturated fatty acids including palmitic acid (16:0) and stearic acid (18:0) were positively, and the unsaturated fatty acids including oleic acid (18:1n-9) and linoleic acid (18:2n-6) were negatively correlated with liver enzymes tests. In regression analysis with adjustment for body mass index, the elevated liver enzymes tests were positively associated with total saturated fatty acids (p=0.52, p<0.001) and negatively with total monounsaturated fatty acids (p=0.47, p<0.001) contents of CSF.

Conclusion: CSF fatty acids may be linked to peripheral markers of liver function, suggesting an indirect impact of central fatty acids on hepatocytes function and metabolism. Further clinical attention and research is warranted to elucidate associations of central fatty acids to liver disease in human.

PI41 DISASTER IN HIV PATIENTS: SEVEN CASES WITH QUADRUPLE DEADLY CO-INFECTION, SHIRAZ, IRAN

Shahab Mahmoudvand1, Ali Pashapour2, Maghsod Shaqrevi3, Amir Meh dizadeh4, Masoud Darabi4

1Students Research Committee, International Branch (Aras), School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 2Department of Emergency Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; 3Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran; 4Department of Biochemistry and Clinical Laboratories, Tabriz University of Medical Sciences, Tabriz, Iran

Presenting Author: Sepideh Ghodoosifar, Email: godoosifar@yahoo.com

ABSTRACT

Background: Some co-infections commonly seen in people infected with human immunodeficiency virus (HIV) e.g. Hepatitis B virus (HBV), Hepatitis C virus (HCV), Tuberculosis (TB), Toxoplasma gondii and Neisseria gonorrohoeae. We aimed to determinate deadly co-infections among HIV patients.

Methods: This retrospective study was performed on 824 HIV patients within a ten year period since 2004. ELISA and confirmation Western Blot test was used for detection of HIV infection. HBsAg, anti-HCV Ab and anti-IgG Ab were using for diagnosis of HBV, HCV and T.gondii respectively. TB and gonorrhea was routinely diagnosed by clinical manifestations and conventional microbiologic tests.

Results: Case No.1, co-infected with HIV-HBV-HCV-TB, 45 years old, CD4+ lymphocyte counts 250 ul Cells/mm. No. 2, co-infected same as No. 1, age 37, CD4+ lymphocyte 1185. No. 3 co-infected with HIV-HBV-TB-gonorrhea, age 44, CD4+ lymphocyte 361. No. 4, co-infected with HIV-HCV-TB-Toxoplasma, age 36, CD4+ lymphocyte 54. No. 5 and 6 co-infected with HIV-HBV-HV- Toxoplasma, age 36 and 51, CD4+ lymphocyte counts 90 and 777, respectively. No. 7, co-infected with HIV-HBV-HCV-gonorrhea, age 36, CD4+ lymphocyte 413. All cases were male and infected with HIV via drug injection route. Moreover, all of them had history of drug addict, prison and HAART therapy. Only exception was case No. 6 which had no history of addiction and HAART therapy, also had unknown transmission rout for HIV acquisition.

Conclusion: As seen in our findings, co-infections are a serious treat for HIV infected patients which may have deadly consequence. Moreover, history of prison and drug addiction seems have significant risk for this condition.

PI51 PDCD1 GENETIC DIVERSITY AT POSITION +7785 HAS NOT SHOWN CORRELATION WITH HCV INFECTION

Razieh Dowran1, Jamal Sarvari2, Nasrollah Erfani2, Mohammad Reza Haghsheh2, Mohammad Reza Fattahi3

1Student Research Committee, Shiraz University of Medical Sciences Shiraz, Iran; 2Department of Bacteriology & Virology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran; 3Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences Shiraz, Iran

Presenting Author: Shahab Mahmoudvand, Email: shahab_mahmoodvand1000@yahoo.com
ABSTRACT

Background: The genetic variations of co-stimulatory molecules such as (PDCD1) programmed cell death 1 gene may affect Pd-1 mRNA expression level which influence the extent of T-cell activity during T-cell mediated immunity. Therefore, it has an important role in chronic infections like HCV infection. We aimed to investigate the association of SNP in PD-1 gene at position +7785 C to T (PD-1.5 or 872) in chronic individual and healthy controls.

Materials and Methods: 162 individuals with chronic HCV infection and 311 healthy controls were enrolled in this study. DNA was extracted from whole blood using salting out method. SNP in PD1 gene was determined by PCR-RFLP method in patients and control groups.

Results: The percentage of CC, CT and TT genotypes at position +7785 C/T in PD-1.5 gene were 42.5%, 43.2% and 14.1%in patients and 44.1%, 39.6% and 16.2% in controls respectively. Distribution of the genotypes and alleles at this locus were not significantly different between patients and controls (P>0.05).

Conclusion: Regarding the data, polymorphisms at PD-1.5 position might not affect the chronicity of HCV infection. Investigating of other SNPs in PD1 gene is suggested.

P153 NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY IN CHILDREN: REVIEW ARTICLE

Sina Dindarian1, Mahdi Bagheri2

1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran

Abstract

Context: Non-alcoholic fatty liver disease (NAFLD) is the term for a wide range of conditions caused by a build-up of fat within the liver cells. NAFLD is probably the most common cause of liver disease among children in industrialized countries. In this article we aimed to review the current knowledge and ideas concerning pediatric non-alcoholic fatty liver disease, with a focus on its relationship with the obesity.

Evidence Acquisitions: The relevant English published papers were searched using online databases of PubMed, Science Direct, and ISI Web of Science. We summarized the findings of 20 relevant studies in this review.

Results: Most of the studies have reported that the pediatric non-alcoholic fatty liver disease is caused by central obesity with insulin resistance and additional factors influencing inflammatory activity (steatohepatitis). Ongoing inflammation leads to fibrosis and end-stage liver disease.

Conclusion: The increased risk of NAFLD in children with higher BMI can be concluded. As obesity is characterized by BMI, there seems to be a meaningful relationship between pediatric NAFLD and obesity.
Fragment Length Polymorphism (RFLP) assay was used for polymorphism genotyping.

**Results:** Among hepatitis B patients, 56.7% were males and 43.3% were females with a mean age of 40.97±13.86 years, comparing to our control group with 42% men and 58% women (mean age: 46.08±14.98). Age and gender associations generated *P*-values less than 0.05 (*P* = 0.03 and *P* = 0.011 respectively); therefore, logistic regression was applied to remove the possible confounding effects. -1082 (rs1800896) genotypes were assessed for all patients, of which 64 (42.7%) were homozygous for AA genotype, 65 (43.3%) were heterozygous and 21 (14%) were homozygous for GG genotype. The frequencies of AA, AG and GG genotypes among controls were 40.7%, 42.7% and 16.7% respectively. No significant difference was observed in the frequency of IL-10 gene polymorphism -1082 (rs1800896) between hepatitis B patients and healthy subjects, even after adjustment for age and gender (*P* = 0.682). Individuals carrying the G allele were more frequent among the control group (38% versus 35.7%), while the incidence of A allele was slightly increased in the patients, however the difference was not statistically significant (*P* = 0.554).

**Conclusions:** No association was observed between -1082 (rs1800896) single nucleotide polymorphism within IL-10 gene and chronic hepatitis B infection; therefore this polymorphism appears to have no influence on susceptibility to chronic hepatitis B.

**P161 EFFECT OF DONOR AGE ON THE RESULT OF LIVER TRANSPLANTATION: REVIEW ARTICLE**

Mahdi Bagheri1, Sina Dindarian1

1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran

**Presenting Author:** Mahdi Bagheri, Email: mbagheri1374@gmail.com

**Abstract**

**Objective:** Numerous researches have been carried out about the effect of donor age on the result of liver transplantation. In this study, we aimed to review the previous papers.

**Methods:** Online databases of PubMed, Science Direct, and Google Scholar were searched using the keywords of “liver transplantation”, “liver graft”, and “donor age”. We studied the papers in which the relationship between donor age and outcome of the transplantation was assessed. 20 English papers were summarized.

**Results:** In most of the studies it was reported that donor age has no effect on the outcome of liver transplantation. However, other factors like gender may alter the effect. Additionally, some of the studies show that the regeneration capacity of the young liver is more than an old one which is not an important factor in health and doesn’t challenge the transplantation.

**Conclusions:** It can be concluded from almost all of the studies that there is no specific relationship between donor age and the result of liver transplantation.

**P162 EVALUATION OF HIGH OXYGEN SATURATION IN CIRRHOTIC PATIENTS**

Ali Adibi, Seyed Mohammad Ali Ghayumi1, Seyed Ali Malek-Hosseini2

1Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 2Shiraz University of Medical Sciences, Shiraz, Iran; 3Organ Transplantation Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran

**Presenting Author:** Ali Adibi, Email: aliadibmail@gmail.com

**ABSTRACT**

**Background:** Hypoxemia is common among cirrhotic patients. It is resulted from the cirrhosis complications like hepatopulmonary syndrome. However, there isn’t any report of cirrhotic patients with hemoglobin oversaturation.

**Aims:** The aim of this study was to investigate the relation of O2 oversaturation in cirrhotic patients who are candidate for liver transplantation.

**Methods:** In this case/control study 384 cirrhotic patients, referred to Shiraz Organ Transplantation Center, were selected. Hemoglobin saturation was measured by ABG (Arterial blood gas). They were divided to two groups; the oversaturated patients (Hb sat O2 ≥98%) as case and the patients with (Hb sat O2 <98%) as control group. Causes of cirrhosis were categorized into seven groups: Autoimmune hepatitis (AIH), Primary sclorosing cholangitis (PSC), cryptogenic, Hepatitis B virus, Hepatitis C virus, Wilson disease, and other causes. Causes of cirrhosis, age, sex, and smoking state, CXR, pulmonary function test (PFT), MELD score, and place of residence’s altitude were compared between case and control groups.

**Results:** 18.5% of patients were oversaturated. 64.7% of control group were male versus 59.2% of case group. Mean age was (39.95±14.786) for control group and was (37.25±16.293) for case group. He-
moğlobin oversaturation in patients with AIH was significantly higher than other causes of cirrhosis (p-value=0.009). Control patients with PSC were significantly higher in proportion to other causes of cirrhosis (p-value=0.04). Place of residence’s altitude was (144.25±565.468) in control group and (1318.52±395.716) in case group which was significantly higher in case group (p-value=.039). There was no significant difference between the age, sex, smoking state, CXR, PFT, and MELD score of case and control groups.

Conclusion: Hemoglobin saturation was higher in patients with AIH than other causes of cirrhosis. Also, oversaturation in cirrhotic patients has correlation with altitude of living site.

**P164 RISK FACTORS OF HCV TRANSMISSION AMONG PATIENTS IN MOTAHARI HEPATITIS CLINIC OF SHIRAZ ON 2014-2015; A CROSS SECTIONAL STUDY**

Amir Hossein Babaei, Mohammad Reza Fattahi1, Moeinodin Abedinirad3

1Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 2Gastroenterology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

**ABSTRACT**

Introduction: Hepatitis C virus (HCV) is the most common cause of chronic liver disease in Iran that may lead to cirrhosis and hepatocellular carcinoma. There is no vaccine till now for HCV, so identification of risk factors is very important to prevent the transmission of HCV. In this study we aimed to determine the route of transmission of HCV infection.

Methods: In this cross sectional study, all the HCV infected patients with positive HCV antibody that referred to Motahari hepatitis clinic in Shiraz on 2014-2015 were asked for possible transmission route of HCV. Age, sex, marital status, history of high risk activities and how realized that they were infected with HCV obtained and analyzed by SPSS version 21.

Results: Of 111 patients, 95 were male (85.58%). The mean age was 42 years. Twenty two patient were single, 77 married and 12 of them divorced or were widow. 61 patients noted past history of IV drug injection. Dental procedure declared by 104 of cases. 46 patients had unsafe sexual contact with their partner. Tattooing reported by 32 persons. 25 infected people had blood transmission in past. 11 patients reported previous imprisonment. Bloodletting reported by 25 patients. The major reason which patients understood their HCV infection were screening tests for liver diseases and blood donation which respectively reported by 95 and 16 patients.

Conclusion: In this study, dental procedure, IV drug injection, unsafe sexual contact, tattooing, blood transmission and bloodletting considered as major possible risk factors of HCV transmission respectively.

**P165 RISK FACTORS AND DEMOGRAPHIC FEATURES OF HBV INFECTION IN PATIENTS REFERRED TO MOTAHARI HEPATITIS CLINIC OF SHIRAZ 2014-2015**

Moeinodin Abedinirad1, Mohammad Reza Fattahi2, Amir Hossein Babaei1

1Medical College, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran; 2Medical College, Gastroenterology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

**ABSTRACT**

Introduction: hepatitis B is one of the major global health issues. According to some reports, the incidence of HBV infection is decreasing in Iran. Diagnosis of new cases despite effective vaccination shows the importance of evaluating the risk factors of HBV. The aim of this study was to determine these risk factors for HBV infection.

Methods: In this cross sectional study, the risk factors of all HbsAg positive patients referred to Motahari hepatitis clinic of Shiraz in 2014-2015 were determined. Demographic features (age, sex and marital status) and other risk factors were analyzed with SPSS version 21.

Results: 88 patients referred to hepatitis clinic in 2014-2015. The mean age was 40, which 58 patients were male (65%). 70 patients were married, 11 patients single, 7 widow or divorced. 74 patients reported dental procedures in past. 23 patients had history of HBV vaccination. 38 patients had history of hepatic disease in their family (65%). 6 patients had history of imprisonment. 4 patients had history of blood transfusion. 17.04% had history of unsafe sexual contact. The major reason which patients referred to the clinic was screening tests.

Conclusion: One important thing to be noticed in our study, is that most of the patients which had HBV infection hadn’t received vaccine. Overall, in pres-
ent study it was concluded that several risk factors of hepatitis - which were determined - supports the result of other studies about HBV.

**P168 OUTCOME OF ACCIDENTAL EXPOSURE PRONE TO BLOOD BORNE VIRAL INFECTIONS IN AN EDUCATIONAL HOSPITAL, 6 YEARS FOLLOW UP**

Shahnaz Sali, Shabnam Tehrani, Sara Abolghasemi

1Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

**ABSTRACT**

**Background:** The risk for transmission of blood-borne viruses (BBVs) such as Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) due to occupational exposure is a major concern in the health care setting.

**Methods:** We reviewed case notes of 337 healthcare workers (HCWs) accidentally exposed to BBVs over six years, from January 2009 to March 2015. The data were reviewed in labbafinejhad hospital; which is specialized 231 bed public tertiary care referral hospital with a total number of 930 HCWs are potentially at accidental risk of acquiring BBVs.

**Results:** The reviewed HCWs cases (337) were classified in to 131 nurses, 80 medical doctors, 59 medical technicians (37 surgical operation, 17 laboratory and 5 radiology technicians),53 cleaning personnel, 13 nursing students and 1 medical student. Injuries were categorized as 258 needle sticks, 40 sharp cuts, 39 blood splashes on eyes. 244 HCWs were exposed to known serologically tested HIV, HBV and HCV negative patients, 44 cases had exposure to HBS Ag positive, 6 cases to HCV Ab positive and 3 cases to HIV seropositive patients. One HIV positive patient was co infected with HCV infection. A total of 40 HCWs had occupational exposure to unknown sero-status patients. HBS Antibody titer of the 44 HCWs, who had HBV exposure, was higher than 10 mlu/ml. HIV exposed HCWs received post exposure prophylaxis (PEP). Follow up of HCWs who had HBV, HCV and HIV exposures showed no acquired infection.

**Conclusion:** Key components in reducing risk for accidental exposure to BBVs are education of HCWs for use of universal precautions, HBV vaccination for achieving appropriate HBS Ab level, implementing proper PEP and medical evaluation follow up.

**P169 EVALUATION OF INTERLEUKIN-27 GENE POLYMORPHISM (2905 T/G) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION**

Samira Mokhtari, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Pedram Azimzadeh, Shaghayehg Derakhshan, Afshaneh Sharifian, Mohammad Reza Zali

1Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Departments of Microbiology, Shahid Beheshti University, Tehran, Iran

**ABSTRACT**

**Background:** Hepatitis C Virus (HCV) infection is one of the major health problems worldwide and has affected more than 185 million people. HCV infection may lead to chronic Liver complications, Liver Cirrhosis and Hepatocellular Carcinoma (HCC) and it is a notable cause of liver-related death and liver transplantation. Variation of disease whether become chronic or complete clearance from the host body is dependent on two factors; viral factors and host immunity. Cytokines have principal roles in the immunity modulation in progression of HCV infection. Interleukin 27 (IL-27) is a member of IL-12 family. IL-27 is pro-inflammatory cytokine and can promote TH1 responses from CD4 naïve T cells. Single nucleotide polymorphisms (SNPs) in interleukin-27 gene are linked to treatment responses. SNPs are important genomic markers which can influence on the activity of IL-27 and may change the outcome of HCV infection. Aim of this study was to determine the association between IL-27 gene polymorphism rs17855750 (2905 T/G) with chronic hepatitis C virus infection.

**Materials and Methods:** Samples were collected from 125 HCV infected patients and 125 samples of healthy controls in Taleghani Hospital and studied. ELISA used as a serological test to examine and confirm chronic HCV infection. The polymerase chain reaction-restriction fragment length polymorphism was performed to determine IL-27 gene polymorphism. DNA-sequencing was applied on 10 percent of samples to validate genotyping results.

**Results:** The genotype frequencies of 2905 T/G polymorphism in the chronic HCV patients were significantly different from the healthy control group (P-value 0.017) with the genotype distribution of TT=80%, TG=20% and GG=0% in patients and TT=89.6%, TG=8.8%, GG=1.6% in healthy group; however there were no significant differences between allele frequencies (P-value 0.156).
**Discussion:** The rate of progression of hepatitis C virus (HCV) infection is variable, likely due to a combination of host genetic and environmental factors. IL-27 importance suggested that it could be a useful candidate for HCV development. The results showed an association between genetic variants of IL-27 SNP 2905 T/G and the evaluation of chronic HCV infection and it may have proinflammatory intent on chronic Hepatitis C Virus infection.

**P176 SEVEN YEARS TRENDS IN PREVALENCE OF MAJOR TRANSFUSION-TRANSMISSIBLE VIRAL INFECTIONS IN SHIRAZ BLOOD TRANSFUSION ORGANIZATION**

Leila Kasraian, Mohammad Hosein Karimi, Nima Naderi

1Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Shiraz University of Medical Sciences Shiraz, Iran;
2Transplantion Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

**ABSTRACT**

**Background:** Increasing blood supply safety is one of the most important goals of blood transfusion services. Evaluation of the prevalence of infectious diseases in blood donors is essential for blood donor screening effectiveness.

**Materials & Methods:** Cross-sectional analyzed the prevalence rate and trend of blood borne infections among Shiraz blood donors during 2007-2014.

**Results:** The prevalence of HIV between 2007 and 2014 were, 0.0096%, 0.0088%, 0.010%, 0.008%, 0.003%, 0.002%, 0.004% and the prevalence of HBS were 0.36%, 0.28%, 0.29%, 0.12%, 0.09%, 0.06% and 0.06% and the prevalence of HCV were, 0.19%, 0.16%, 0.15%, 0.07%, 0.06%, 0.05% and 0.03%. The Cochran Armitage trend test was used for determination trend change. The prevalence of hepatitis B and HIV was decreased from 2007 to 2012 (P<0.001). The prevalence of HCV did not change over 2007 to 2009. The prevalence rate of HIV and HCV decreased significantly from 2010 (P<0.05). The prevalence of HBS, HCV and HIV was more in first-time and male blood donors (P<0.05).

**Conclusion:** The results showed that the strategies used for improving blood safety were efficient. The prevalence rate of TTVI in Shiraz blood donors is less than normal population and decreased over the time that may be due to effective donor selection, the lower prevalence rate of TTVI in donor population and more safety measures implanted in recent years in Iran.

**P178 THE PRE-S2 SEQUENCE MUTATIONS ASSOCIATED WITH HBV DISEASE CONSEQUENCE AMONG DIFFERENT PATIENTS GROUPS**

Mohammad Taghiabadi, Jamal Sarvari, Seyed Younes Hosseini, Ali Akbar Gorzin, Hamidreza Monavari, Mohamad-Reza Fattahi

1Department of Bacteriology & Virology, University of Medical Sciences, Shiraz, Iran;
2Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran;
3Department of Clinical Virology, Iran University of Medical Sciences, Tehran, Iran

**Presenting Author:** Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

**ABSTRACT**

**Background:** Sequence variation in Pre-s2 gene of Hepatitis B Virus (HBV) is enumerated as important viral factors contributed to infection outcome. While some studies indicated the role of Pre-S2 mutations in diseases progression when evaluated in B and C genotypes, the data supporting this idea on genotype D is limited.

**Objectives:** The aim of this study was to investigate if deletion mutation in Pre-S2 region attributed to disease progression. Here, the mutations in this region compared among patients with Hepatocellular carcinoma (HCC), Liver cirrhosis (LC) and asymptomatic carriers (ASCs). Material methods and Patients: A total of 60 sera samples were collected from patients infected with HBV. They included 30 asymptomatic carrier (ASCs) individuals samples (22 male and 8 female, mid age: 51) and 30 HCC and Cirrhosis (20 HCC and 10 LC), (26 male and 4 female, mid age: 53). The viral DNA was extracted using DNA extraction kit, and then HBV Pre-s2 gene region were amplified by Nested-Polymerase Chain Reaction (Nested-PCR). Finally, DNA sequences of samples were qualified by Alignment tools (BLAST) then each group was compared with each other by Several Multiple Sequencing Alignment softwares.

**Results:** The results indicated higher rate of mutation among ASCs group than HCC/LC samples. In 26 ASCs samples (from total 30 samples) 13 critical point mutations in Pre-s2 was detected. Furthermore, in 7 ASCs, 7 deletion mutations were also revealed after analysis. In opposite, 5 point mutations and no sign of deletion mutation in LC/HCC group were confirmed after comparing their sequence with references.

**Conclusion:** The rate of deletion/point mutations in asymptomatic carriers was so higher than HCC and
Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

ABSTRACT

Background: Mutations in Pre-S1 gene of Hepatitis B Virus (HBV) is accounted as one of the most important viral factors associated with HBV infection outcomes. On behalf of researchers some deletion/substitution mutations of Pre-S1 region might be responsible for disease progressive toward Liver Cirrhosis (LC) and hepatocellular carcinoma (HCC).

Objectives: The aim of this study was to compare the mutations of Pre-s1 region of HBV genotype D in HCC, Liver cirrhosis and asymptomatic carriers (ASCs).

Material and Methods: A total of 60 sera samples were collected from patients infected with HBV. They included 30 asymptomatic carrier (ASCs) individuals samples (22 male and 8 female, mid age: 51) and 30 HCC and Cirrhosis (20 HCC and 10 LC), (26 male and 4 female, mid age: 53). The viral DNA was extracted using DNA extraction kit, and then HBV Pre-s1 gene region was amplified by Nested-Polymerase Chain Reaction (Nested-PCR). Finally, DNA sequences of samples were evaluated first by online Alignment tools (BLAST) then groups were compared together by Several Multiple Sequencing Alignment softwares.

Results: Out of 60 subjects, 33 samples had 14 deletion and 21 point mutations in Pre-s1 region. In 18 ASCs samples, 11 critical substitution mutations, 14 deletions and in 15 HCC/LC, 10 substitution mutations but not any deletions, were confirmed through comparing with other reference sequences. There were less critical mutations detected in Pre-s1 and interestingly no deletion mutations among LC/HCC groups.

Conclusion: In spite of our imagination, higher rate of mutations among asymptomatic carriers was clearly delineated here which indicated that in genotype D, Pre-s1 deletions are dispensable factors for progression of disease toward cirrhosis and HCC.

Presenting Author: Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

Poster Presentations

P180 THE SURVEY OF PRE-S1 SEQUENCE MUTATIONS AMONG DIFFERENT HBV INFECTED GROUPS, POSSIBLE ASSOCIATION WITH DISEASE CONSEQUENCE

Mohammad Taghiabadi, Jamal Sarvari, Seyed Younes Hosseini, Ali Akbar Gorzin, Hamidreza Monavari, Maryam Moini, Mohammad-Reza Fattahi

1Department of Bacteriology & Virology, University of Medical Sciences, Shiraz, Iran; 2Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Department of Clinical Virology, Iran University of Medical Sciences, Tehran, Iran

Presenting Author: Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

ABSTRACT

Background: Mutations in Pre-S1 gene of Hepatitis B Virus (HBV) is accounted as one of the most important viral factors associated with HBV infection outcomes. On behalf of researchers some deletion/substitution mutations of Pre-S1 region might be responsible for disease progressive toward Liver Cirrhosis (LC) and hepatocellular carcinoma (HCC).

Objectives: The aim of this study was to compare the mutations of Pre-s1 region of HBV genotype D in HCC, Liver cirrhosis and asymptomatic carriers (ASCs).

Material and Methods: A total of 60 sera samples were collected from patients infected with HBV. They included 30 asymptomatic carrier (ASCs) individuals samples (22 male and 8 female, mid age: 51) and 30 HCC and Cirrhosis (20 HCC and 10 LC), (26 male and 4 female, mid age: 53). The viral DNA was extracted using DNA extraction kit, and then HBV Pre-s1 gene region was amplified by Nested-Polymerase Chain Reaction (Nested-PCR). Finally, DNA sequences of samples were evaluated first by online Alignment tools (BLAST) then groups were compared together by Several Multiple Sequencing Alignment softwares.

Results: Out of 60 subjects, 33 samples had 14 deletion and 21 point mutations in Pre-s1 region. In 18 ASCs samples, 11 critical substitution mutations, 14 deletions and in 15 HCC/LC, 10 substitution mutations but not any deletions, were confirmed through comparing with other reference sequences. There were less critical mutations detected in Pre-s1 and interestingly no deletion mutations among LC/HCC groups.

Conclusion: In spite of our imagination, higher rate of mutations among asymptomatic carriers was clearly delineated here which indicated that in genotype D, Pre-s1 deletions are dispensable factors for progression of disease toward cirrhosis and HCC.

Presenting Author: Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

P184 THE DOMINANT PREVALENCE OF GENOTYPE D AMONG DIFFERENT HBV INFECTED PATIENT GROUPS, A STUDY FROM REFERRAL CENTER IN SOUTH OF IRAN

Jamal Sarvari, Mohammad Taghiabadi, Seyed Younes Hosseini, Ali Akbar Gorzin, Hamidreza Monavari, Mohammad-Reza Fattahi

1Department of Bacteriology & Virology, University of Medical Sciences, Shiraz, Iran; 2Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 3Department of Clinical Virology, Iran University of Medical Sciences, Tehran, Iran

Presenting Author: Mohammad Taghiabadi, Email: taghiabadi_mohammad@yahoo.com

ABSTRACT

Background: There are more than 7 well described Hepatitis B Virus (HBV) genotypes worldwide. This genetic diversity has been associated with differences in clinical outcomes. In Iran, genotype D was determined as the most common type of virus. In compare to others, Genotype D virus harbors a natural omission in Pre-s1, from aa 2 to 13.

Objectives: The aim of this study was to determine HBV genotype through survey in Pre-s1 region and phylogenetic analysis coincidently.

Materials and Methods: A total of 60 sera samples were collected from patients infected with HBV. They included 30 asymptomatic carriers (22 male and 8 female, mid age: 51), 20 HCC and 10 Cirrhotic patients (26 male and 4 female, mid age: 53). The viral DNA was extracted using DNA extraction kit, and then HBV Pre-s1 gene region was amplified by Nested-Polymerase Chain Reaction (Nested-PCR). The sequences of samples were qualified by Alignment tool (BLAST) then they were compared with other genotypes sequences from Genbank by Multiple Sequencing Alignment.

Results: The sequencing results showed that all of 60 samples were containing genotype D related deletions in Pre-s1 region, from aa2 to 13, which was indicative for the presence of this genotype in all of them. Blast analysis and phylogenetic survey was also supportive of this finding.

Conclusion: In our region, HBV genotype D is dominant among different patient groups in Shiraz- Iran.
P190 WILLINGNESS TO RECEIVE TREATMENT FOR HEPATITIS C VIRUS AMONG DRUG INJECTORS ON METHADONE PROGRAM: IMPLICATIONS FOR HCV KNOWLEDGE AND EDUCATION

Zahra Alam-Mehrjerdi, Javad Salehi Fadardi, Fenglian Xu, Mehran Zarghami, Kate Dolan
1Program of International Research and Training, National Drug and Alcohol Research Centre, Faculty of Public Health and Community Medicine, University of New South Wales, Sydney, Australia;
2Department of Psychology, Faculty of Education and Psychology, Ferdowsi University, Mashhad, Iran;
3National Drug and Alcohol Research Centre, Faculty of Public Health and Community Medicine, University of New South Wales, Sydney, Australia;
4Department of Psychiatry, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Presenting Author: Zahra Alam-Mehrjerdi, Email: a.mehrjerdi@gmail.com

ABSTRACT

Objectives: Although, Persian people who inject drugs (PWID) have high prevalence of Hepatitis C Virus (HCV), a few receive HCV treatment mostly because of poor knowledge about the infection and its treatment. We assessed the factors which were associated with willingness for HCV treatment in a group of PWID who were maintained on methadone treatment.

Methods: 187 PWID were surveyed in seven community methadone programs in Tehran. Participants reported socio-demographic characteristics, the details of drug use and injection and HCV knowledge and treatment history. They were also serologically tested for HCV.

Results: The study found that 28.3% were HCV seropositive. 85% were unaware of their HCV status. Awareness of current HCV status (OR = 3.43; 95% CI, 1.33-7.26; P = 0.012), knowledge of available HCV treatment centers in the community (OR = 7.9; 95% CI, 1.24-5.38; P = 0.004), lifetime attendance at a HCV educational program (OR = 2.9; 95% CI, 2.33-8.56; P < 0.001) and recent attendance at Self-Help Groups (OR = 4.6; 95% CI, 3.43-9.36; P < 0.001) were significantly predictors of willingness for HCV treatment among PWID on methadone program.

Conclusion: PWID on methadone program should be provided with HCV education. More attention should be paid to increasing willingness for HCV treatment. The roles of educational programs and Self-Help Groups in encouraging PWID for HCV treatment require further studies.

P192 SHARED METHAMPHETAMINE INJECTION AMONG TREATMENT SEEKERS AND POSITIVE HEPATITIS C STATUS: THE FIRST REPORT FROM PERSIAN IRAN

Zahra Alam-Mehrjerdi, Zohreh Abarashi, Alireza Noroozi, Leila Arshad, Mehran Zarghami

ABSTRACT

Shared methamphetamine injection is an emerging route of drug use among Persian methamphetamine injectors. It is a primary vector for hepatitis C virus. The aim of the current study is to determine the prevalence and correlates of shared methamphetamine injection in a sample of Iranian methamphetamine injecting treatment seekers in the south of Tehran. We surveyed male and female methamphetamine injectors at three drop-in centers and 18 drug-use community treatment programs. Participants reported socio-demographic characteristics, drug use, high risk behaviours, current status of viral infections and service use for drug treatment. Bivariate and multivariate logistic regression models were used to test associations between participants’ characteristics and shared methamphetamine injection. Overall, 209 clients were recruited; 90.9% were male; 52.6% reported current methamphetamine injection without any shared injection behaviour and 47.4% reported current shared methamphetamine injection. Shared methamphetamine injection was found to be primarily associated with living with sex partners (AOR 1.25, 95% CI 1.13-1.98), reporting three years of dependence on methamphetamine injection (AOR 1.61, 95% CI 1.27-2.12), injection with pre-filled syringes in the past 12 months (AOR 1.96, 95% CI 1.47-2.42), homosexual sex without condom use in the past 12 months (AOR 1.95, 95% CI 1.21-2.25), the paucity of NA group participation in the past 12 months (AOR 0.67, 95% CI 0.41-0.99), the paucity of attending psychotherapeutic sessions in the past 12 months (AOR 0.44, 95% CI 0.28-0.96) and positive hepatitis C status (AOR 1.98, 95% CI 1.67-2.83). Deeper exploration of the relation-
ship between shared methamphetamine injection and sexual risk among Iranian methamphetamine injectors would benefit HIV/sexually transmitted infection prevention efforts. In addition, existing psychosocial interventions for methamphetamine-injecting population may need to be adapted to better meet the risks of shared methamphetamine injectors.

**P211 INTERLEUKIN-28B (RS12979860) GENE VARIATION AND TREATMENT OUTCOME AFTER PEGINTERFERON PLUS RIBAVIRIN THERAPY IN PATIENTS WITH GENOTYPE 1 OF HEPATITIS C VIRUS**

Tahmine Tavakoli

*Gastroenterology Department, Birjand University of Medical Sciences, Birjand, Iran*

**Presenting Author:** Tahmine Tavakoli, Email: tahminetavakoli95238@yahoo.com

**ABSTRACT**

**Background:** The success of treatment of chronic hepatitis C (CHC) with pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV) is affected by several host, viral, and treatment factors. This study was designed to describe the association of interleukin (IL) 28B genotypes for rs12979860 with sustained virologic response (SVR) in patients with genotype 1 CHC infection treated with PEG-IFN-α-2 and RBV.

**Materials and Methods:** Interleukin-28B genotype in 100 studied patients was detected by tagman real-time polymerase chain reaction. Before treatment blood samples were obtained, then patients were treated for 48-week with a combination therapy using of the PEG-IFN-α-2 and RBV. SVR evaluated 6 months after stopping therapy, and was defined as undetectable plasma hepatitis C virus-RNA.

**Results:** Among studied patients, 65% were IL-28B CT, 27% CC, and 8% TT. In all studied patients, SVR was 58.3%, relapse 15.6%, and null virological response 26.1%. SVR rates were 76.9% in IL-28B-CC, 56.4% in IL-28B-CT, and 12.5% in IL-28B-TT patients. Relapse rates were 7.7% in IL-28B-CC, 12.9% in IL-28B-CT, and 62.5% in IL-28B-TT patients. There was a significant difference between response to treatment in patients IL-28B-CC, CT, and TT (P = 0.003). IL-28B genotype CC, (odds ratio = 0.053, 95% confidence interval; 0.005-0.54, P = 0.03), was the independent predicting factor.

**Conclusion:** Interleukin-28B was an important predictor of CHC treatment outcome with Peg-IFN-α and RBV. IL-28B-CC seems to be more important than IL-28B-CT/T in predicting positive treatment response.

**P215 THE EFFECTS OF SINGLE NUCLEOTIDE POLYMORPHISM OF IL28B GENE (RS12980275) ON TREATMENT RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN IN IRANIAN PATIENTS WITH HEPATITIS C**

Mahsa Zamanian, Golnaz Asaadi Tehrani, Zohre Sharifi

*Genetics Department, Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran; IBTO, Iranian Blood Transfusion Organization Research Center, Tehran, Iran*

**Presenting Author:** Mahsa Zamanian, Email: mahsa_emad@yahoo.com

**ABSTRACT**

**Background and Purpose:** The standard of care treatment for infected patients with HCV is based on a combination of pegylated interferon alpha and ribavirin. Recently, the rs12980275 SNP polymorphism, located upstream of the interleukin 28B gene, was shown to be strongly associated with response to anti-HCV therapy. This study investigated the distribution of the (G/A) polymorphism with sustained virologic response (SVR) to chronic Hepatitis C virus infection among Iranian population.

**Material and Methods:** This cross-sectional study was performed in 75 blood samples including 50 SVR positive and 25 negative samples from individuals suffering from chronic hepatitis C, and 50 healthy controls. DNA was extracted from the samples and the frequency of the polymorphism was analyzed using PCR-ARMS method. Finally, the products were detected on agarose gel.

**Results:** In the analysis of the data for G/A polymorphism, the GG genotype was identified in 29 patients of whom 28 (39.4%) achieved SVR, while the GA heterozygous was found in 75 patients and SVR was achieved in 42 (59.2%). Finally, the AA was detected in 14 patients and only one (1.4%) responded to treatment.

**Conclusion:** Patients with G allele had significantly higher SVR rate than those with A allele. These data suggest that genotype detection of rs12980275 SNP may be useful as an important predictive biomarker for SVR in patients infected with HCV. However, further studies with more samples lead to more validated results.
P217 ASSOCIATION OF IL28B GENE (RS8099917) POLYMORPHISM WITH TREATMENT RESPONSE IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON/RIBAVIRIN IN IRAN

Mahsa Zamanian1, Golnaz Asaadi Tehrani1, Zohre Sharifi2

1Genetic, Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran; 2IBTO, Iranian Blood Transfusion Organization Research Center, Tehran, Iran

ABSTRACT

Background and Purpose: The standard of care treatment for infected patients with HCV is based on a combination of pegylated interferon alpha and ribavirin. Recently, the rs8099917 SNP polymorphism, located upstream of the interleukin 28b gene, was shown to be strongly associated with response to anti-HCV therapy. This study investigated the distribution of the (G/T) polymorphism with sustained virologic response (SVR) to chronic Hepatitis C virus infection among Iranian population.

Materials and Methods: This cross-sectional study was performed in 75 blood samples including 50 SVR positive and 25 negative samples from individuals suffering from chronic hepatitis C, and 50 healthy controls. DNA was extracted from the samples and the frequency of the polymorphism was analyzed using PCR-ARMS method. Finally, the products were detected on agarose gel.

Results: In the analysis of the data for G/T polymorphism, the TT genotype was identified in 45 patients of whom 42 (59.4%) achieved SVR, while the GT heterozygous was found in15 patients and SVR was achieved in 12 (39.2%). Finally, the GG was detected in 4 patients and only one (1.4%) responded to treatment.

Conclusion: Patients with T allele had significantly higher SVR rate than those with G allele. These data suggest that genotype detection of rs8099917 SNP may be useful as an important predictive biomarker for SVR in patients infected with HCV. However, further studies with more samples lead to more validated results.

P220 SEROPREVALENCIE STUDY OF HEPATITIS B VIRUS AMONG HOSPITALIZED INTRAVENOUS DRUG USERS IN TEHRAN, IRAN (2012-2013)

Tahmineh Kandelouei1, Seyed Masoud Hosseini2, Latif Gachkar3, Foad Davoodbeglou3, Maryam Asli4, Maryam Vaezjalali4

1Department of Microbiology, Shahid Beheshti University, Tehran, Iran; 2Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Department of Immunology, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Department of Microbiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

Background: Injecting drug use is a major cause of both morbidity and mortality worldwide. Injection drug use has been the most growing rout of drug abuse in Iran in the past decade and it has been responsible for the transmission of blood born infections such as Hepatitis B Virus (HBV) infection.

Methods: This was a cross-sectional investigation which conducted on 100 male Intravenous Drug Users (IDU). The records of 100 IDUs hospitalized from 2012-2013 at Loghman Hospital were reviewed. Their serum samples were tested for the presence of HBsAg (Hepatitis B Surface Antigen) by Enzyme-linked Immunosorbert Assay (ELISA).

Results: The Prevalence of HBsAg was 1%. The majority Prevalence of HBsAg was among adults age 25-45 years.

Conclusion: Many studies highlighted that blood borne viral infections are prevalent among intravenous drug users. Fewer infected cases in this study promises that in case of performing on time detriment prevention and decreasing measures, will cause future satisfying results in this case.

P221 VERTICAL HEPATITIS IN A FIVE YEAR PERIOD IN ZABOL HOSPITAL

Aliyeh Sargazi1, Zahra Sepehri2, Atefeh Sargazi3, Solyman Saravani4

1Medical Faculty, Zabol University of Medical Sciences, Zabol, Iran; 2Research Department, Zabol University of Medical Sciences, Zabol, Iran; 3Civil Department, Sistan and Baloochestan University, Zahedan, Iran; 4EDC, Zabol University of Medical Sciences, Zabol, Iran

ABSTRACT

Introduction: Hepatitis B and C are the most common causes of hepatitis among newborns in developing countries. Vertical hepatitis refers to hepatitis transmitted from the mother to the infant during pregnancy, at the time of delivery, or during the first 28 days after birth. In this study we tried to evaluate
vertical hepatitis situation in the only educational hospital of Zabol city from 2009 till 2013.

**Materials and Methods:** In this descriptive study, patient’s documents of labor ward were studied from 2009 till 2013. Information related to hepatitis infected newborns collected using checklist tool. Data analyzed using SPSS-21 software.

**Results:** Our study showed out of total 47,987 deliveries, 853 (1.78%) stillbirths, 325 (0.68%) abortions and 46809 (97.40%) successful births were recorded in which 266 (0.56%) cases were related to hepatitis in Zabol hospital in 2009-13. Out of all hepatitis infected newborns 50, 79, 67, 30 and 40 were recorded in 2009, 2010, 2011, 2012 and 2013 respectively. Average recorded number of hepatitis in each month was 4.43 in this duration. Our analysis showed no significant change in hepatitis incidence in Zabol in this period. *(p>0.05)*

**Conclusion:** According to the results, vertical hepatitis is a major health problem in Zabol. This subject could be related to women’s hygiene and mother’s health. We are suggesting new managements of health policies and paying more attention to vertical hepatitis problem in this area.

---

**P229 LONG TERM THERAPEUTIC CONSEQUENCES IN PATIENTS WITH AUTOIMMUNE HEPATITIS**

Mohammadreza Abdollahi1, Neda Khalilian1, Mohammadhossein Somi1

1Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

**ABSTRACT**

**Introduction:** Autoimmune hepatitis (AIH) is a chronic inflammation of the liver, the cause of which is unknown. The long-term outcome of patients with AIH has not been well-defined. The aim of this study was to clarify the long-term outcomes and determinants of outcome in patients with AIH.

**Methods and Material:** In this cohort, a total of 150 AIH patients were enrolled in the study. Patients were followed up for an average of 60 months. Clinical, biochemical, pathological and imaging data were gathered from all the patients at both the beginning and the end of the follow-up with 3 checkpoints between these time periods. Results are expressed as mean ± SD. *P* < 0.05 was statistically significant.

**Results:** One hundred and fifty patients, 113 female, 37 male, mean age 42.39 ± 14.58 years, participated in the study. The most common symptoms were icter (88.7%), fatigue (84.7%), pruritus (80%) and loss of appetite (36.6%) at diagnosis. Seventy-three patients (48.7%) reached remission; thirty-four patients (22.7%) relapsed, thirty-two patients (21.3%) had incomplete response and eleven patients (7.3%) had treatment failure. Predictors for disease progression were age at presentation of 20-40 years and number of relapses *(P< 0.05)*. The prognosis of patients experiencing two or more relapses was significantly poorer than that of patients with remission or a single relapse both in univariate *(P < 0.001)* and multivariate *(P < 0.001)* analyses.

**Conclusions:** Repeated relapses of disease are significantly associated with a poorer long term consequences in patients with autoimmune hepatitis.

---

**P230 EVALUATION OF SURVEILLANCE SYSTEMS FOR HEPATITIS B IN IRAN**

Seyed Hossein Hosseinij1, Kourosh Etemad2, Hassan Maka-rem3

1Epidemiology Department, Shahid Beheshti University Medical Science, Kashmar, Iran; 2Epidemiology, Shahid Beheshti University Medical Science, Tehran, Iran; 3Health Center Khalil Abad, Mashhad University Medical Science, Kash- mar, Iran

**Presenting Author:** Seyed Hossein Hosseini, Email: hosseinij33@gmail.com

**ABSTRACT**

Hepatitis B is one of the major health problems in the world, especially in developing countries so that in 70 to 80 percent of chronic hepatitis caused by hepatitis B virus and the main cause of mortality in hepatitis, hepatitis B is. The surveillance system for hepatitis B in the following target groups for screening are recommended: Donors who early in the incubation period of the disease can HBV transfer and detection techniques are known to remain so in achieving blood stored absent any risk of contamination but by PCR cannot be enabled (the now do not operate anywhere in the world) * Pregnant women in the third trimester and so screening is recommended for all women in America. Screening of different target groups in America than Iran is so that in America, in addition to the target groups which are screened in Iran, People in areas with moderate and high rates of hepatitis B (incidence greater than or equal to 2%) and those not vaccinat-
ed as children whose parents are in areas with high rates of hepatitis B (HBsAg prevalence of greater than or equal to 8%) were born. and homosexual men are not part of the target group screening in Iran. Including opportunities for surveillance of hepatitis B can be found at different levels of health and family physicians cited that Family physicians have a plan to increase the percentage of people who care and early detection of the disease and prevent progression to cirrhosis and liver cancer caused by hepatitis decrease. Another strength of the system of care for hepatitis B hepatitis B vaccine produced by the Pasteur Institute in 86 years that the work of the hepatitis B vaccine was sufficient. Planning to identify carriers of hepatitis, health care necessary to prevent the infection of others, testing of hepatitis B in pregnant women contamination and timely action to prevent the contamination of infected mothers, the contact with infected needles (needle stick) and health education, disease transmission, …. Of the things that can increase knowledge and changing attitudes and behaviors lead to control of this disease.

**P242 LACK OF ASSOCIATION BETWEEN IL12A SINGLE NUCLEOTIDE POLYMORPHISM (RS6887695G/C) AND CHRONIC HEPATITIS B VIRUS INFECTION**

Sedigheh Heidarian

1Department of Virology, Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

**Presenting Author:** Sedigheh Heidarian, Email: seh.heidarian@gmail.com

**ABSTRACT**

**Background:** The hepatitis B virus (HBV) infection is considered to be one of the most important etiological factors of liver complication around the world. Interactions of host immune responses with HBV have a crucial role in the outcome of the infection. IL12 is an important pro-inflammatory cytokine that stimulates natural killer cells and T-lymphocytes to produce IFN-α, promotes T-helper 1 responses and enhances CD8+ cytotoxic T-cell activity. These unique properties of IL12 indicate that it might play an important role in control and clearance of HBV. On the other hand, single nucleotide polymorphisms (SNPs) are presumed to be associated with the differential production of cytokines. In this study, association of IL12A rs6887695 G/C polymorphism with chronic HBV infection has been investigated.

**Materials and Methods:** Genotypes distribution of IL12A rs6887695 were determined in 120 HBV chronic patients and 120 healthy controls using polymerase chain restriction fragment length polymorphism (PCR-RFLP) method.

**Results:** The frequencies of rs6887695GG, GC and CC genotypes in the patients with chronic infection were 58.30%, 35% and 6.70% respectively and in healthy controls were 50%, 44.20%, 5.80%. No statistically significant difference was detected in IL12A rs6887695 genotypes between patient and control groups (P value =0.26).

**Conclusions:** Our findings suggest that IL12A rs6887695 SNP is not associated with chronic HBV infection in the studied Iranian population.

**P250 SEROPREVALENCE OF HEPATITIS A AND HEPATITIS E VIRUS IN HEALTHY BLOOD DONORS FROM TEHRAN, IRAN**

Khashayar Hesamizadeh1, Maryam Keshvari2, Seyed Moayed Alavian1, Heidar Sharafi3, Azar Najafi Tireh-Shabankareh4

1Virology, Iran University of Medical Sciences, Tehran, Iran;
2Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran;
3Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran,
4Nanotechnology, Tehran University of Medical Sciences, Tehran, Iran

**Presenting Author:** Khashayar Hesamizadeh, Email: kh.hesamizadeh@gmail.com

**ABSTRACT**

**Background:** Hepatitis A virus (HAV) and hepatitis E virus (HEV) are both transmitted by the fecal oral route, and known as leading causes of acute viral hepatitis in the world, especially in developing countries. There is a lack of updated data on HAV and HEV seroprevalence in Iran. The aim of this study was to determine the seroprevalence of HAV and HEV among group of blood donors in Tehran, Iran.

**Methods:** A cross sectional study was performed in July 2014 until December 2014 on a total of 559 blood donors referred to Tehran Blood Transfusion Center. The samples were studies for antibodies to HAV and HEV. Data were statistically analyzed using SPSS, were calculated the mean, median, mode, standard deviation and P-value using Fishers Exact test or Chi-squared test. To HAV and HEV antibodies positivity, a P-value less than 0.05 was considered to be statistically significant.

**Results:** In the present study, 559 blood donors, 536 were men (95.9%) and 23 were women (4.1%) analyzed
P259 CLONING OF HCV CORE+1 GENE IN BACULOVIRUS EXPRESSION SYSTEM

Fahimeh Safarnezhad Tameshkel, Pooneh Rahimi, Mohammad Reza Khataminejad

1Department of Biology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran; 2Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran

Presenting Author: Fahimeh Safarnezhad Tameshkel, Email: fahime.1615@yahoo.com

ABSTRACT

Background: The new detected HCV protein “Core+1” made from the ribosomal frame shift in Core region is an important candidate for diagnostic tools.

Objectives: This study was conducted to design a recombinant Bacmid plasmid expressing the HCV 1a Core+1 sequence in Baculovirus expression system for further diagnostic applications

Materials and Methods: In this study DNA sequence of Core+1 gene amplified by PCR for producing an insert sequence that containing this gene. The targeted gene has been cloned in pFastBac HTb vector and sequenced after treating by XbaI/NcoI restriction endonucleases. After confirming the cloning of target gene clone product transformed to the Baclovirus (DH10bac) system. Blue-white screening of colonies and PCR confirmed the transformation.

Results: The Cloning of pFastBac vector with the purified PCR product of HCV Core+1 was confirmed. Finally, the recombinant Bacmid was successfully transformed in DH10Bac.

Conclusions: The recombinant Bac-Core+1 expression vector is considered as an important tool to transfact the sf9 cell line and expression the Core+1 protein.

P286 SURVEILLANCE AND EPIDEMIOLOGY OF HEPATITIS B, C, D AND G IN KHUZESTAN PROVINCE, SOUTHWEST IRAN- A REVIEW.

Amir Pouremamali, Manoochehr Makavndi, Farhad Pouremamali

1School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran; 2Jundishapur University of Medical Sciences, Ahvaz, Iran; 3School of Medicine, Faculty of Health, Tabriz University of Medical Sciences, Tabriz, Iran

Presenting Author: Amir Pouremamali, Email: pooremamali@gmail.com

ABSTRACT

Background: This article provides a brief overview of the different types of viral hepatitis, including their epidemiology, clinical features. HBV and HCV infectious are frequent causes of acute and chronic hepatitis worldwide and leading causes for hepatic cirrhosis and cancer. HDV is acquired only by coinfection with HBV or by superinfection of an HBV carrier. Hepatitis G virus belonging to the family Flaviviridae. This virus is transmitted via blood and blood products.

Materials and Methods: Information obtained from previous investigations on HBV, HCV, HDV and HGV infections have yielded a better knowledge about hepatitis. All descriptive/analytical cross-sectional studies/surveys from 2002 to 2011 that have sufficiently declared objectives, proper sampling method with identical and valid measurement instruments. Reverse transcription polymerase chain reaction (RT-PCR) was used for RNA detection from serum samples of hepatitis patients.

Results: Among intravenous drug users, 103 patients (30.9%) had HCV and 12 (3.6%) had HBV infection. On thalassemia patients, the prevalence rate of anti-HCV was 28.1%, 46 of anti-HCV positive patients were also HCV RNA positive. Out of 214 hemodialysis patients, 34 were positive for anti-HCV and 11 for HBsAg. Among Haemophilia Patients, prevalence rate of HBsAg and anti-HCV were 1.1% and 54%, respectively. co-infection of HGV with HCV and HBV was determined at 6% and 8%, respectively. And HDV prevalence was 11.5%.

Conclusions: The harmonisation and strengthening of HBV and HCV surveillance at the Khuzestanean level is of utmost importance to obtain more robust data on these diseases.

P295 COMPARATIVE STUDY ON THE CHEMICAL AND MEDICINAL EFFECTS OF INDIGENOUS SILIYBUM MARIANUM FROM EGYPT AND
MEDICINAL SILYMARIN FROM CHINA ON THE TREATMENT OF LIVER FIBROSIS ON FEMALE ALBINO RA

Engy Mohamed Abo Elfetoh1
1Biochemistry, Faculty of Science, Tanta, Egypt

Presenting Author: Engy M.A. Elfetoh, Email: engy531@hotmail.com

ABSTRACT
Liver fibrosis is one of the common problems affecting on the human health. Many herbal and medicinal plants and their extracts are widely studied. The medical Chinese silymarin got a bright reputation in relieve the liver fibrosis. A total of 72 female Albino rats were divided into six groups; G1 (Control), G2 (Fibrosis), G3 (Chinese silymarin), G4 (Fibrosis + Chinese silymarin), G5 (Egyptian silymarin extract), G6 (Fibrosis + Egyptian silymarin extract). Results showed that, serum liver enzymes activities (ALT, AST and GGT) and tissues MDA were significantly decreased in G5 compared to those in G1 and G2. Serum total protein and tissues GST, CAT enzymes activities, total thiol and TAC were significantly increased in G5 as compared to G1 and G2. The results revealed that, the Egyptian plant extract improved liver function and its oxidative stress parameters in comparison with the Chinese silymarin, in case of liver fibrosis. Also, GC-MS showed that the Egyptian silymarin has more peaks than that of Chinese silymarin. The smaller peak area in the Egyptian silymarin extract was about one third the big one in the Chinese silymarin. The Egyptian silymarin extract have extra components that needs further study for its identification.

P303 OCCULT HEPATITIS B INFECTION IN HEPATITIS C PATIENTS WITH HAEMATOLOGICAL DISORDERS

Nematollah Jonaidi-Jafari1, Mohammad Saeid Rezaee-Zavareh2, Javad Tavallaei-Nosratabadi1, Reza Ajudani2, Ali Aliakbar Ramezani-Binabaji2, Hamidreza Karimi-Sari2, Morteza Izadi2, Reza Ranjbar2, Seyed Moayed Alavian1
1Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
2Students’ Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, Iran;
3Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
4Middle East Liver Diseases Center (MELD), Tehran, Iran

Presenting Author: Reza Ajudani, Email: reza_ibut7@yahoo.com

ABSTRACT
Background: Occult hepatitis B infection (OBI) is recognized by finding HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum) of patient with negative testing for HBV surface antigen (HBsAg). OBI is seen in Hepatitis C virus (HCV) infected patients and also one of the important mechanism for transmission of HBV and HCV is via blood transfusion. In this study we want to assess the prevalence of OBI among Iranian patients with haematological disorders (thalassemia, hemophilia and some other coagulation factors deficiency) infected with CHC.

Patients and Methods: In this descriptive cross sectional study, all patients with haematological disorders (thalassemia, hemophilia or other coagulation factors deficiency) who had CHC infection simultaneously, that referred to Tehran Hepatitis Center (TCH) between 2009 and 2010 enrolled to this study. OBI identification was based on the serum HBV-DNA detection. Data analysis was done with SPSS.

Results: All of patients were HBS Ag negative and HCV RNA positive. Only 145 patients had HBV DNA evaluation. (126 male and 19 female patients) The mean age was 28.12 ± 8.6 years. Thirty five patients had thalassemia, 95 patients had hemophilia, and 15 patients had coagulation factors deficiency. Serum HBV-DNA was negative for all cases.

Conclusions: Based on our results, it seems that there is no OBI case in the chronic HCV infected patients with thalassemia and bleeding disorders especially Hemophilia. But for getting a better decision about OBI screening particularly in transfusion centers and use of a comprehensive screening method, more original studies with more precise laboratory techniques and more sample size is still needed.

P304 SEROPREVALENCE OF HEPATITIS A VIRUS AMONG IRANIAN SOLDIERS

Morteza Izadi1, Ali Aliakbar Esfahani2, Hadi Hassannia1, Nematollah Jonaidi-Jafari1, Fatemeh Rahmati Najarkolaei1, Mohammad Saeid Rezaee-Zavareh2
1Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
2Health Management Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
3Department of Medical Immunology, Tehran University of Medical Sciences, Tehran, Iran;
4Student’s Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran

Presenting Author: Mohammad Saeid Rezaee-Zavareh, Email: dr_rezaee@live.com
ABSTRACT

Background: Hepatitis A virus (HAV) is highly contagious in individuals living in crowded conditions such as military centers. This study try to investigate the seroprevalence of HAV immunity among Iranian soldiers and determine whether vaccination should be used for military draftees.

Patients and Methods: In this cross-sectional study, a total of 1554 soldiers were recruited through random clustering sampling. Serum anti-HAV antibody was measured by Enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using SPSS.

Results: A total of 1554 male soldiers with age ranged from 18 to 34 years (mean age: 21.2±1.9 y) at baseline were evaluated. Overall, 80.3% of the analyzed specimens were anti-HAV seropositive. The seroprevalence rates increased significantly with the age.

Conclusions: Our results suggest that generally vaccination for HAV is not necessary for Iranian military draftees. But the vaccination is recommended for high-risk groups including anti-HAV seronegative soldiers.

P305 ARE WOMEN WITH POLYCYSTIC OVARIAN SYNDROME AT A HIGH RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE; A META-ANALYSIS

Mahdi Ramezani-Binabaj,1 Mohsen Motalebi2, Hamidreza Karimi-sari3, Mohammad Saeid Rezaee Zavareh1, Seyed Moayed Alavian4

1Students' Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran;
2Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;
3Students Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran;
4Middle East Liver Diseases Center (MELD), Tehran, Iran

ABSTRACT

Context: Insulin resistance is a hallmark of metabolic syndrome (MS). It has been proposed that both polycystic ovarian syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD) are correlated with insulin resistance. Therefore, PCOS and NAFLD can be attributed with insulin resistance and therefore MS. The aim of this meta-analysis was to determine whether PCOS patients are at a high risk of NAFLD.

Evidence Acquisition: Google scholar, Scopus, ISI Web of Science, Embase, MEDLINE, and some Iranian databases such as scientific information database (SID), IranMedex, and MagIran were searched to identify relevant studies. We included all papers regardless of their language from January 1985 to June 2013. By using data on prevalence of NAFLD in patients with and without PCOS, odds ratio (OR) with 95% confidence intervals (CIs) were calculated in each study. Chi-squared test was used to assess heterogeneity between studies.

Results: We finally included seven eligible studies. According to chi-squared test, there was a significant heterogeneity (73.6%) between studies (P = 0.001). NAFLD prevalence was significantly higher in patients with PCOS compared to healthy control, with an overall OR of 3.93 (95% CI: 2.17, 7.11). There was no significant publication bias based on Begg’s and Egger’s tests.

Conclusions: According to the results of this meta-analysis, there was a high risk of NAFLD in women with PCOS. We suggest evaluating patients with PCOS regarding NAFLD.
AUTHORS INDEX

A
Abarashi 22
Abdollahi 6, 25
Abedin Dorkoosh 5
Abedinirad 18
Abou Elfetoh 28
Abolghasemi 19
Adib 17
Ajardy 7
Ajudani 28
Akbani 5
Akbani Sari 5
Alam-Mehrjerdi 22
Alavian 5, 6, 13, 14, 28, 29
Amini-Bavil-Olyaee 6
Anvar 13
Arshad 22
Asadi Tehrani 23, 24
Asli 24
Ataei 12
Azarkar 11
Azarpira 5
Azimzadeh 16, 19
Azizi Saraji 13

B
Babaei 18
Bagheri 16, 17
Bahari 14
Bakhshizadeh 14
Baran 10
Bashiri 11
Bijari 11
B Lankarani 5

D
Darabi 15
Darvishpour kakhki 11
Davoodbeglou 24
Derakhshani 19
Dindarian 16, 17
Dokhtkhairkhah 13
Dolan 22
Doosti 14
Dowran 15

E
Ehsani 7
Erfani 15
Esfahani 28
Esmaielzadeh 14
Etemad 25

F
Fattahi 5, 15, 18, 20, 21
Fotouhi Chahouki 8

G
Gachkar 24
Ganji 14
Geramizadeh 5
Ghanaie 14
Ghavami 5
Ghayumi 17
Ghodoosifar 15
Gorzin 20, 21
Goshayeshi 14

H
Haghsenas 15
Hassannia 28
Hatef Salmanian 7
Hekmat 14
Hemami 5
Herbers 6
Hoseini 14
Hosseini 16, 19, 20, 21, 24, 25

I
Izadi 28

J
Jafari-Rouhi 15
Janghorbani 12
Jazayeri 9
Jonaidi Jafari 28
Jonaidi-Jafari 28

K
Kandelouei 24
Karimi 20
Karimi-sari 28, 29
Kasraian 20
Kebriaeezadeh 5
Keshavarz 5
Keshvari 5, 14
Keyvani 5
Khalilian 6, 25
Khanahmad 7
Khanaghma 16
Khashe 15
Khataminejad 27

Khodayar 12
Khorvash 12

M
Mahdavi 7
Mahmoudvand 15
Makarem 25
Makavndi 27
Malek-Hosseini 17
M Coombs 5
Mehdizadeh 15
Memarnejadian 7
Mohammadi-Yeganeh 12
Mohammadzadeh 7
Mohabbi 16, 19
Moin 21
Mokhtari 19
Monavari 20, 21
Motalebi 29
Motamedifar 15
Motavaf 13
Motevalli 14

N
Naderi 20
Namvar 13
Nikfar 5
Noroozi 22

P
Paryan 12
Pashapour 15
Peymani 5
Pourremamali 27
Pourii 6

R
Rahimi 8, 12, 27
Rahmati Najarkolaei 28
Ramezani-Binabj 28, 29
Ranjbar 28
Rezaee-Zavareh 28, 29
Roohvand 7
Roushan 11

S
Sabour 5
Sadat 14
Sadat Mirfakhar 16
Sadeghi 9
Sadeghizadeh 13
AUTHORS INDEX

Safarnezhad Tameshkel  27
Sajadian Fard  8
Salehi Fadardi  22
Sali  19
Saravani  24
Sargazi  24
Sarvari  15, 20, 21
Sedigh Ebrahim-Sarai  15
Sepehri  24
Shaaker  15
Sharifi  23, 24
Sharifian  16, 19
Shirmast  13
Shirvani-Dastgerdi  6
Shoaei  12
Soleimanjahi  7
Somi  6, 25
T
Tacke  6, 9
Taghiabadi  20, 21
Tavakoli  23
Tavallaei- Nosratabadi  28
Tehrani  19
Trautwein  6
V
Vaezjalali  24
Vahabpour  8
Vakili  12
Vosooghinia  14
X
Xu  22
Y
Yagmur  6
Yaran  12
Yazdanian  7
Yeganeh  5
Z
Zali  16, 19
Zamanian  23, 24
Zarghami  22
Ziaee  11